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Abstract
In the United States, cancer is the second leading cause of death following heart disease.
Although, a variety of treatment regimens are available, cancer management is complicated
by the complexity of the disease and the variability, between people, of disease progression
and response to therapy. Therefore, advancements in the methods and technologies for
cancer diagnosis, prognosis and therapeutic monitoring are critical to improving the
treatment of cancer patients.
The development of improved imaging methods for early diagnosis of cancer and of
near real-time monitoring of tumor response to therapy may improve outcomes as well as
the quality of life of cancer patients. In the last decade, imaging methods including
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), single photon
emission computed tomography (SPECT), and positron emission tomography (PET), have
revolutionized oncology. More recently optical techniques, that have access to unique
molecular reporting strategies and functional contrasts, show promise for oncologic imaging
This dissertation focuses on the development and optimization of a fiber-based, videorate fluorescence molecular tomography (FMT) instrument. Concurrent acquisition of
fluorescence and reference signals allowed the efficient generation of ratio-metric data for
3D image reconstruction. Accurate depth localization and high sensitivity to fluorescent
xiv

targets were established to depths of >10 mm. In vivo accumulation of indocyanine green
dye was imaged in the region of the sentinel lymph node (SLN) following intradermal
injection into the forepaw of rats. These results suggest that video-rate FMT has potential as
a clinical tool for noninvasive mapping of SLN.
Spatial and temporal co-registration of nuclear and optical images can enable the fusion
of the information from these complementary molecular imaging modalities. A critical
challenge is in integrating the optical and nuclear imaging hardware. Flexible fiber-based
FMT systems provide a viable solution. The various imaging bore sizes of small animal
nuclear imaging systems can potentially accommodate the FMT fiber imaging arrays. In
addition FMT imaging facilitates co-registering the nuclear and optical contrasts in time. In
this dissertation, the feasibility of integrating the fiber-based, video-rate FMT system with a
commercial preclinical NanoSPECT/CT platform was established. Feasibility of in vivo
imaging is demonstrated by tracking a monomolecular multimodal-imaging agent (MOMIA)
during transport from the forepaw to the axillary lymph nodes region of a rat. These coregistered FMT/SPECT/CT imaging results with MOMIAs may facilitate the development
of the next generation preclinical and clinical multimodal optical-nuclear platforms for a
broad array of imaging applications, and help elucidate the underlying biological processes
relevant to cancer diagnosis and therapy monitoring.
Finally, I demonstrated that video-rate FMT is sufficiently fast to enable imaging of
cardiac, respiratory and pharmacokinetic induced dynamic fluorescent signals. From these
measurements, the image-derived input function and the real-time uptake of injected agents
can be deduced for pharmacokinetic analysis of fluorescing agents. In a study comparing
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normal mice against mice liver disease, we developed anatomically guided dynamic FMT in
conjunction with tracer kinetic modeling to quantify uptake rates of fluorescing agents.
This work establishes fiber-based, video-rate FMT system as a practical and powerful
tool that is well suited to a broad array of potential imaging applications, ranging from early
disease detection, quantifying physiology and monitoring progression of disease and
therapies.
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Preface
Chapter 1: Accurate and rapid detection of diseases is of great importance for assessing the
molecular basis of pathogenesis, preventing the onset of complications, and implementing a
tailored therapeutic regimen. The ability of optical imaging to transcend wide spatial imaging
scales ranging from cells to organ systems has rejuvenated interests in using this technology
for medical imaging. Moreover, optical imaging has at its disposal diverse contrast
mechanisms for distinguishing normal from pathologic processes and tissues. To
accommodate these signaling strategies, an array of imaging techniques has been developed.
Importantly, light absorption, and emission methods, as well as hybrid optical imaging
approaches are amenable to both small animal and human studies. Typically, complex
methods are needed to extract quantitative data from deep tissues. This chapter focuses on
the development of optical imaging platforms, image processing techniques, and molecular
probes, as well as their applications in cancer diagnosis, staging, and monitoring therapeutic
response.

Chapter 2: I have developed a fiber-based, video-rate fluorescence diffuse optical
tomography (DOT) system for noninvasive in vivo sentinel lymph node (SLN) mapping.
Concurrent acquisition of fluorescence and reference signals allowed the efficient generation
of ratio-metric data for 3D image reconstruction. Accurate depth localization and high
sensitivity to fluorescent targets were established in to depths of >10 mm. In vivo
accumulation of indocyanine green (ICG) dye was imaged in the region of the SLN
following intradermal injection into the forepaw of rats. These results suggest that video-rate
xvii

fluorescence DOT has significant potential as a clinical tool for noninvasive mapping of
SLN.

Chapter 3: Spatial and temporal co-registration of nuclear and optical images can enable the
fusion of the information from these complementary molecular imaging modalities. A critical
challenge is in integrating the optical and nuclear imaging hardware. Flexible fiber-based
fluorescence mediated tomography (FMT) systems provide a viable solution. The various
imaging bore sizes of small animal nuclear imaging systems can potentially accommodate the
FMT fiber imaging arrays. In addition FMT imaging facilitates co-registering the nuclear and
optical contrasts in time. In this chapter, I combine a fiber-based FMT system with a
preclinical NanoSPECT/CT platform. Feasibility of in vivo imaging is demonstrated by
tracking a monomolecular multimodal imaging agent (MOMIA) during transport from the
forepaw to the axillary lymph nodes (ALNs) region of a rat.
The fiber-based, video-rate FMT imaging system is composed of 12 sources (785nm
and 830nm LDs) and 13 detectors. To maintain high temporal sampling, the system
simultaneously acquires ratio-metric data at each detector. A three-dimensional finiteelement model derived from CT projections provides anatomically based light propagation
modeling. Injection of a MOMIA intradermally into the forepaw of rats provided spatially
and temporally co-registered nuclear and optical contrasts. FMT data was acquired
concurrently with SPECT and CT. Incorporation of SPECT as a prior in the FMT
reconstruction integrated the optical and nuclear contrasts.
Accurate depth localization of phantoms with different thicknesses was accomplished
with an average center-of-mass error of 4.1 +/- 2.1 mm between FMT and SPECT
xviii

measurements. During in vivo tests, Fluorescence and radioactivity from the MOMIA were
co-localized in spatially coincident regions with an average center-of-mass error of 2.68 +/1.0 mm between FMT and SPECT for ALNs localization. Intravital imaging with surgical
exposure of the lymph node validated the localization of the optical contrast.
The feasibility of integrating a fiber-based, video-rate FMT system with a commercial
preclinical

NanoSPECT/CT

platform

was

established.

These

co-registered

FMT/SPECT/CT imaging results with MOMIAs may facilitate the development of the next
generation preclinical and clinical multimodal optical-nuclear platforms for a broad array of
imaging applications, and help elucidate the underlying biological processes relevant to
cancer diagnosis and therapy monitoring.

Chapter 4: Dynamic fluorescence imaging is an emerging technology that can provide
enhanced non-invasive functional and molecular level detail. Optical tracer kinetic modeling
combined with fluorescence dynamic tomography is a non-invasive quantification method
that allows extraction of clinically or experimentally relevant parameters related to biological
or molecular processes and monitoring their alterations due to pathology. Blood plasma
concentration measurement of fluorescence over time is a key tool required for accurate
optical tracer kinetic modeling to estimate the relevant and desired parameters. Anatomically
guided dynamic fluorescence mediated tomography (DyFMT) provides a viable solution to
obtain image derived input function. In this chapter, I demonstrate that video-rate FMT is
fast enough to enable imaging of cardiac, respiratory and pharmacokinetic induced dynamic
fluorescent signals. From these measurements, the image-derived input function and the

xix

real-time uptake of injected agents can be deduced in normal mice and in mice with
experimentally induced liver disease.

Chapter 5: Cancer-related enzyme activity can be detected noninvasively using activatable
fluorescent molecular probes. In contrast to “always on” fluorescent molecular probes,
activatable probes are relatively non-fluorescent at the time of administration due to
intramolecular fluorescence resonance energy transfer (FRET). Enzyme mediated hydrolysis
of peptide linkers results in reduced FRET and increased of fluorescence yield. Separation
signal from active and inactive probe can be difficult with conventional intensity-based
fluorescence imaging. Fluorescence lifetime (FLT) measurement is an alternative method to
detect changes in FRET. Thus I investigated FLT imaging for in vivo detection of FRETbased molecular probe activation in an orthotopic breast cancer model. Indeed, the
measured FLT of the enzyme-activatable molecular probe increased from 0.62 ns just after
injection to 0.78 ns in tumor tissue after 4 hours. A significant increase in FLT was not
observed for an “always-on” targeted molecular probe with the same fluorescent reporter.
These results show that FLT contrast is a powerful addition to preclinical imaging because it
can report molecular activity in vivo due to changes in FRET. Fluorescence lifetime imaging
exploits unique characteristics of fluorescent molecular probes that can be further translated
into clinical applications including non-invasive detection of cancer-related enzyme activity.
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Chapter 1
General Introduction
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1.1

Introduction
The application of optical imaging and spectroscopy in medicine and biomedical

research has captivated the attention of many scientists, engineers, and clinicians because
of the compactness, low cost, and ability of the technology to provide functional and
molecular information (Hebden, Arridge and Delpy). In the process of optical imaging,
light interaction with biological tissues leads to a number of photophysical events such as
absorption, scattering, and emission of light. Each of these events can be utilized to
obtain biochemical and morphological information about specific cell or tissue of
interest. The diverse contrast mechanisms provided by optical methods constitute the
basis of several optical imaging platforms that include spectroscopic, planar, diffuse, and
hybrid biomedical optics methods (Tuchin; Vo-Dinh; Wang; Wax and Backman). In fact,
the diversity of imaging and therapeutic platform available to researchers is a unique
strength of optical technology.
Typically, optical imaging begins with the absorption of light by endogenous or
exogenous chromophores to provide contrast between diseased and normal surrounding
tissue. In absorption imaging, contrast is generated by the differential concentration of
the chromophores in tissues (Niemz; Knappe, Frank and Rohde). The absorbed light
can dissipate as heat to surrounding tissue, a phenomenon that is useful in photothermal
therapy or photoacoustic imaging (Knappe, Frank and Rohde; Wang). A fraction of the
absorbed light can be re-emitted at longer wavelengths than the incident. This emitted
light is called autofluorescence if it originates from endogenous chromophores.
Autofluorescence is widely used to characterize the metabolic status of tissue. An
2

important example is the classification of tissue as normal or benign and malignant
tumors based on the optical properties of flavin adenine dinucleotide (FAD) and
reduced nicotinamide adenine dinucleotide (NADH). Autofluorescence imaging and
other endogenous fluorophores have easier path to human translation since the signaling
biomolecules are naturally produced by the body. The term fluorescence is generally
reserved for light emission generated by exogenous contrast agents. This class of optical
imaging platform will be discussed in details in several sections below. In a variant of
fluorescence imaging, spontaneous light emission can be induced by a biochemical
reaction, such as the luciferase-catalyzed oxidation of luciferin (O'Neill et al.; Dothager
et al.). This process is termed bioluminescence. Bioluminescence imaging is widely used
to unravel the molecular basis of biochemical processes at the molecular levels in cells
and small animals. The simplicity of the imaging method, high throughput capability, and
the high detection sensitivity and specificity makes this approach attractive for drug
development, monitoring treatment response, and molecular interactions in animal
models of human diseases. Unfortunately, there is no clear path to human translation in
the current state of the technology due to foreign genetic materials (O'Neill et al.;
Dothager et al.). In addition to absorption and emission imaging, incident light is highly
scattered in heterogeneous media such as tissues. Since light scattering pattern is
dependent on tissue morphology, it is used to generate exquisite structural information
of target tissues (Wax and Backman). For example, the up-regulation or down-regulation
of structural proteins such as collagen can be used to report the invasiveness of tumors
and the status of wound healing (Yeh et al.).
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Beyond cell and small animal studies, the next frontier is the translation of optical
imaging and spectroscopy to humans. Major advances have been made in both
instrumentation and tissue-targeted molecular probes that are suitable for human use.
These advances promise to change the landscape of conventional diagnostic and
treatment monitoring methods (Achilefu; Arridge; Arridge and Hebden; Celli et al.;
Erickson and Godavarty; Gibson, Hebden and Arridge; Hebden, Arridge and Delpy;
Vo-Dinh). Interestingly, optical imaging has come a long way from the early days of
diaphanography, which used simple transillumination light scanning method (Monsees,
Destouet and Totty), to modern day diffuse optical tomography and spectroscopy.
Unlike diaphanography, which resulted in poor sensitivity in breast cancer detection
(58%, based on histologic validation of biopsied samples)(Drexler, Davis and Schofield),
new techniques have incorporated state-of-the-art imaging algorithms, highly sensitive
detectors, and an array of light sources to delineate scattering from absorption
parameters. This approach promises to improve both sensitivity and specificity of
current imaging systems in clinics. Several optical imaging methods are already used in
clinical practice. Notable among these is optical coherent tomography, which furnishes
exceptionally high spatial resolution of tissue structure at microscopic level (Huang et al.;
Boppart et al.). The method, which was first introduced for ophthalmologic applications
(Swanson et al.), has been expanded to cardiac imaging (Bezerra et al.) and cancer
diagnosis (Tearney et al.). Recent studies have also demonstrated the applicability of
high-resolution optical fiber-based devices for in vivo characterization of tissues
(Badizadegan et al.; Flusberg et al.; VoDinh et al.). Incorporation of this technique into
endoscopes will expand their applications to virtually all current endoscopic procedures
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and enhance the capabilities of intravital microscopy. Thus, in addition to aiding disease
diagnosis, optical imaging is anticipated to be effective in monitoring treatment response
in cancer patients (Choe, Corlu, et al.; Kukreti, Cerussi, Tanamai, et al.; Choe).
This chapter focuses on the development of optical imaging platforms, image
processing techniques, and molecular probes, as well as their applications for cancer
diagnosis, staging, and monitoring therapies. Emphasis is placed on emerging optical
methods that are translatable to humans and specific to cancer.

1.2

Optical Contrast Agents
Optical imaging techniques can measure both inherent tissue optical properties (e.g.

scattering, absorption and autofluorescence) and those of exogenous molecular probes
(e.g. fluorescence, photoacoustic) with high temporal resolution. The spectrally
dependent light absorption and propagation properties in tissues (Figure 1.1) based on
optical properties of specific molecules are used to produce imaging contrast in optical
molecular imaging. A variety of optical contrast agent-mediated optical methods are
widely used for preclinical imaging of cancer and monitoring of therapeutic responses.
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Figure 1.1: Light propagation in turbid medium such as biological tissue.

1.2.1

Endogenous Tissue Optical Contrast

Light interaction with biological tissues results in a number of photophysical events
such as its absorption and scattering. Scattering is defined as the deviation of a photon
path as it propagates through a heterogeneous medium such as a biological tissue. The
most useful approximation describing light scattering in tissue is based on Mie’s theory
(Tuchin; Wang and Wu; Richards-Kortum and Sevick-Muraca). Mie’s scattering relates
to the scattering of light by particles of the same or larger size than the wavelength of the
incident light. The intensity of Mie scattered radiation is weakly dependent on
wavelength and tissue morphology (Tuchin; Wang and Wu). Diffusely reflected and
transmitted photons provide diagnostic information about the tissue. For instance, the
change in size and number of the major light scatterers in tissue, such as mitochondria
and cell nuclei, can be used to differentiate neoplastic from healthy tissues based on the
6

spectral variation of the scattered light. To illustrate this point, the diameter of cell nuclei
in normal epithelial tissues has been found to be approximately 4-7 µm compared to 20
µm in cancerous tissues, which also contain multiple nuclei (Tuchin; Wang and Wu).
Hence, scattering properties of tissues provide insight into morphological and structural
changes that can be used to identify abnormal variations of the tissue’s spatial
characteristics. Detailed theoretical basis and practical applications of light scattering in
tissues for biomedical imaging has recently been reported (Wax and Backman).
Absorption is a phenomenon that results in the capturing of light energy by
chromophores, exciting their electrons from the ground to higher energy levels (VoDinh; Niemz; Tuchin; Wang and Wu). The chromophores dissipate their energy in the
form of heat or by a radiative decay when their excited electrons return to the ground
state (Wang and Wu; Niemz; Tuchin). Oxy-hemoglobin (HbO2) and deoxyhemoglobin
(HbR), melanin, myoglobin, and water are the predominant endogenous absorbers in the
600-1000nm. Interestingly, the absorption coefficient of these chromophores are low
between 700 and 900 nm relative to the visible wavelengths, creating an optimal spectral
window that allows light to travel in deep tissue and the photons to undergo multiple
scattering events before attenuation (Richards-Kortum and Sevick-Muraca; Tuchin;
Wang and Wu). For these reasons, most optical methods for deep tissue imaging and
diffuse optical tomography in particular, operate in this “transparent optical window”.
As mentioned above, variations in total hemoglobin and oxygen saturation can be
inferred from tissue absorption based on the differences in oxy-hemoglobin and deoxyhemoglobin optical spectra. For tumor imaging, high level of HbO2 may suggest an
increase in arterial blood supply, creation of new blood supply pathway to tumors, or
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high metabolic oxygen demand reminiscent of highly proliferating tumors. In contrast,
an increase in HbR concentration implies a decrease in oxygen saturation associated with
the presence of hypoxic tumor or high oxygen extraction. Both HbO2 and HbR serve as
important biomarkers for tumor diagnosis and monitoring the outcome of a therapeutic
intervention. To illustrate this approach, Choe et al. (Choe, Corlu, et al.) demonstrated
the feasibility of localizing invasive carcinoma of breast tumor with diffuse optical
tomography by quantifying the total hemoglobin and oxy-hemoglobin concentrations.
The authors observed that the tumor volume and total hemoglobin concentration
decreased from 21.4±1.4 µM to 9.1±0.5 µM over the course of the chemotherapy. A
variety of similar studies have been reported and a recent paper by Leff et al. (Leff et al.)
summarized the findings of optical-based breast imaging studies from different research
groups.
Tissue autofluorescence occurs when excited electrons of endogenous fluorophores
emit light of different wavelength after photon absorption (Wang and Wu; Tuchin;
Berezin and Achilefu). The importance of autofluorescence for studying cells and tissues
lies mostly in their potential for diagnostic applications. It is also used as a research tool
to understand the underlying mechanisms of molecular interactions and signaling
processes under their native conditions (Berezin and Achilefu; Monici; Richards-Kortum
and Sevick-Muraca). The most important fluorophores for autofluorescence in cells and
tissues are amino acids (phenylalanine, tyrosine and tryptophan), which are the essential
building blocks of proteins and enzymes; nicotinamide and flavins, which regulate cell
metabolism; porphyrins, which are responsible for the transport of respiratory gases;
structural proteins (collagen and elastin), which are responsible for rigidity and flexibility
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of tissues and organs; and fluorescent pigments (melanin, lipofuscin), which are markers
of many age-related pathologies (Berezin and Achilefu; Monici). For instance,
endogenous fluorophores such as flavin adenine dinucleotide (FAD) and reduced
nicotinamide adenine dinucleotide (NADH) are used to monitor changes in the
metabolic level of tissues by taking the ratio of their fluorescence intensity obtained from
one- and two-photon confocal microscopy (Richards-Kortum and Sevick-Muraca) as
well as with diffuse spectroscopy (C. Zhu et al.). The fluorescence intensity of NADH is
found to be higher than its oxidized form (NAD+), and vice versa for the FAD.
However, a number of challenges associated with the complex nature of
autofluorescence, such as weak fluorescence signals, the use of damaging UV light or
high power two-photon visible excitation, and difficulties in interpretation of images,
limits its broad applications in molecular imaging and disease diagnosis. Thus, the use of
autofluorescence depends on the intended application or tissue type. For example, skin
diseases and a variety of endoscope-based applications that do not require deep tissue
analysis have benefited from autofluorescence imaging. Exciting studies using
endoscopes for examining gastrointestinal neoplasia in clinical settings have been
reported (Imaeda et al.; Falk). Note that fluorophores from diet also contribute
significantly to autofluorescence. This type of autofluorescence could increase
background signal during tissue imaging with exogenous imaging agents. However,
several methods are available to minimize this side effect, including fasting the animal,
the use of special diet with low autofluorescence, and techniques to spectrally suppress
autofluorescence (Bhaumik, Depuy and Klimash; Bouchard et al.)
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1.2.2

Exogenous Tissue Contrast Agents

Exogenous contrast agents are playing a crucial role in advancing optical molecular
imaging for wide array of applications, ranging from studying cell regulation mechanisms
to cancer diagnosis. The advantage of exogenous optical contrast agents lies in the ability
to optimize their structure for a wide variety of disease-specific studies. This is generally
accomplished by tuning their spectral properties. Optical probes that absorb and emit in
the visible spectral range are mainly used for superficial tissue imaging (for example skin
cancer detection) and studies of cell mechanisms. However, the signal obtained from
optical probes in the visible range is biased by background tissue autofluorescence signal,
which is negligible in the NIR spectral range. Therefore, molecular probes in the NIR
region are primarily used for deep tissue in vivo imaging and to minimize
autofluorescence. Optical contrast agents are classified into different groups based on
their fluorophore structure, spectral range, and specific activity. Examples of common
optical probes are cyanine dyes, boron-dipyrromethene (BODIPY) based molecules, and
quantum dots (Akers and Achilefu; Berezin and Achilefu). The sources of contrast could
be due to change in intensity, fluorescence lifetime or polarization associated with
biological processes. Preferably, optical molecular probes should have high molar
absorptivity, high fluorescence quantum yield (for fluorescence imaging), and good
photo-stability. For activatable probes, they should preferably be enzymatically stable to
non-target enzymes and biochemical reactions. In addition, chemical stability is
important for a new generation of molecular probes carrying targeting groups for
selective delivery to tumors. Such targeted conjugates further enhance the sensitivity and
specificity of optical contrast agents for early detection of cancer.
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1.2.2.1 Non-Targeted Optical Contrast Agents
Non-targeted optical contrast agents typically accumulate in tumors because of
increased tumor vascularization and/or leaky blood vessels (Achilefu; S. I. Achilefu et al.;
Licha, Hessenius, et al.; Licha, Riefke, et al.). The approved use of the NIR fluorescent
dye, indocyanine green (ICG), by the US Food and Drug Administration for nonimaging indications has allowed adoption as non-specific and biocompatible optical
imaging agent in humans. Thus, ICG is widely used to test the performance and
specifications of optical imaging devices in clinical and preclinical studies. It is also used
as a generic imaging agent for cancer imaging. For example, Intes et al. (Intes, Ripoll, et
al.) localized suspicious mass in breast cancer patients after bolus administration of ICG.
Additionally, Alacam et al. introduced a computational model to analyze ICG
pharmacokinetics in cancerous tumors vs. normal tissues using NIR diffuse optical
tomography (Alacam, Yazici, Intes, et al.; Alacam, Yazici, Intes, Nioka, et al.). In these
studies, the authors provided temporal images of the distribution of ICG from breast
cancer patients. Using a computational model, they reported significant difference in the
pharmacokinetic rates as well as ICG concentration in the tumor compared to the
surrounding normal tissue region. Recently, Sevick-Muraca et al. (Sevick-Muraca et al.)
demonstrated the feasibility of employing NIR fluorescence imaging for dynamic lymph
trafficking and lymph node mapping in humans non-invasively after bolus injection of
ICG in the arms and legs of patients. The impressive dynamic images demonstrated the
potential of using optical molecular imaging for sentinel lymph node mapping in cancer
staging. However, since non-targeted optical probes suffer from low selectivity for
tumors, the use of molecular probes that selectively target cancer tissue, could further
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improve the information content obtained, particularly in the identification of positive
nodes for biopsy.

1.2.2.2 Cancer Biomarkers and Targeted Probes
Many of the current efforts in tumor imaging have focused on the design of cancertargeting molecular probes. One approach is to identify cancer biomarkers, such as overexpressed proteins or diagnostic enzymes in the tumor and the appropriate molecule
(ligand) that binds to a target biomarker with high affinity. Once the biomarkers and the
ligands are established, the targeted molecular probe can be prepared by conjugating the
targeting moiety to the dye. Cancer biomarker identification is essential for early
diagnosis, prognosis and staging of cancers as well as monitoring and optimizing
therapies. In general, cancer biomarkers for targeted optical imaging are biomolecules
such as cell surface protein receptors or enzymes, which are over-expressed in the active
form in neoplasms compared to normal tissues. Many of these biomarkers are
commonly shared by a number of malignant tumors (Ludwig and Weinstein; Sidransky).
Below I will review two classes of the molecular targeted probes: non activatable and
activatable.
Receptor Targeted optical molecular probes. Optical imaging with receptor-targeted
molecular probes relies on the increased concentration of the probe on the target tissue
to generate increased optical (fluorescence or photoacoustic) signal. Historically, this was
the first type of tumor-targeted molecular probes (S. Achilefu, R. B. Dorshow, et al.).
Today, a majority of the tumor targeting molecular probes belongs to this class and a
large number of the constructs are now commercially available.
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Initial studies relied on the labeling of large biomolecules such as antibodies for
optical imaging (Ballou et al.; Clauss and Jain). These pioneering studies gave rise to the
highly promising advances in the molecular imaging of tumors. For example, the
transmembrane tyrosine kinase receptor proteins in which a member of the epidermal
growth factor receptor family (EGFR), the human epidermal growth factor receptor 2
(HER-2/neu), is commonly over-expressed has become a favorite target for optical
imaging of tumors. The key function of EGFR is intracellular signal transduction to
control cell proliferation, migration and cell survival (Ross and Fletcher; Ross, Fletcher,
Bloom, Linette, Stec, Symmans, et al.; Nicholson et al.). Up-regulation of HER-2/neu
has been associated with tumor growth and metastasis (Ross and Fletcher; Cobleigh et
al.). Trastuzumab (also known as Herceptin) is a humanized monoclonal antibody that
has high affinity for HER-2 receptors (Ross, Fletcher, Bloom, Linette, Stec, Clark, et al.;
Vogel et al.). Therefore, a number of efforts in optical imaging of cancer involved
conjugating fluorescent dyes with Trastuzumab to image HER2 positive tumors
(Koyama et al.; Sampath et al.).
Although large proteins and antibodies hold great promise for the development of
tumor targeting agents with high binding affinity to the target receptor, interest in the
use of small peptide-based molecular probes have continued to gain grounds in receptortargeting imaging platforms. A prominent example is the targeting of somatostatin
receptors with fluorescent dye labeled somatostatin peptide analogues such as octreotate
(S. Achilefu, H. N. Jimenez, et al.; Licha, Hessenius, et al.). The somatostatin receptor
served as a target in whole-body animal imaging study with receptor-targeted NIR
fluorescent probe. In this example, a NIR fluorescent dye analogue to ICG but with
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conjugatable functionalities, cypate, was covalently linked to octreotate. Using a planar
fluorescence reflectance imaging system, the in vivo distribution of the molecular probe
in rodents bearing pancreatic acinar carcinomas was obtained (S. Achilefu, R. B.
Dorshow, et al.). This study demonstrates the high uptake of the optical molecular probe
in the tumor. Since this pioneering study, numerous studies have validated the use of
NIR dye-labeled peptides to image tumors in living systems as described below.
Another example of a cancer biomarker that is over-expressed in a wide range of
tumors are the αvβ3 integrins, which are heterodimeric cell surface proteins composed of
one one α and one β transmembrane glycoprotein subunits (Giancotti "Complexity and
Specificity of Integrin Signalling"). The key function of integrins is to regulate multiple
intracellular signal transduction pathways leading to cell proliferation, differentiation,
migration and survival (Giancotti "Integrin Signaling: Specificity and Control of Cell
Survival and Cell Cycle Progression"; Giancotti "Complexity and Specificity of Integrin
Signalling"; Giancotti and Ruoslahti). The αvβ3 integrin is of special interest because it is
upregulated in various tumors as well as angiogenic blood vessels (Giancotti "Integrin
Signaling: Specificity and Control of Cell Survival and Cell Cycle Progression"; Guo and
Giancotti). The αvβ3 integrin has high affinity for the naturally occurring
proteins/polypeptides possessing Arg-Gly-Asp (RGD) peptide sequence [68]. The utility
of a NIR fluorescent probe decorated with RGD peptides in tumor imaging has been
reported by many investigators (Achilefu; Haubner et al.; S. Achilefu, S. Bloch, et al.; Ye
et al.). Achilefu et al. [70] also discovered that a variant of RGD peptides possessing the
GRD peptide sequence labeled with cypate selectively accumulates in αvβ3 integrin
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positive tumor (A549) in nude mice. The study was conducted with a simple planar
fluorescence reflectance imaging system. Further microscopic analysis showed that
retention of this molecular probe in the tumor correlated with regions of high expression
of metabolic indicators such as NADH. Thus, this molecular probe appears to selectively
target highly proliferating tumors.
Following by the success of preclinical studies, efforts to move the receptor-targeted
optical imaging to humans have increased recently. The highly compartmentalized nature
of the gastrointestinal system and the ease of accessing this organ with endoscopes have
attracted the first human study of molecular optical imaging of gastrointestinal tumors
with a peptide-based exogenous imaging agent (Hsiung et al.). The fluoresceinconjugated peptide construct was developed to bind more strongly to dysplastic
colonocytes than to adjacent normal cells and demonstrated 81% sensitivity and 82%
specificity. Applications of this approach for image guided intraoperative procedures are
also in progress.
Targeted activatable optical contrast agents are mostly designed to interrogate biological
processes associated with abnormal protease activities and tissue metabolism. Activatable
probes are generally composed of a covalently linked fluorophore pair with different or
similar optical properties in close proximity to each other. For Förster or fluorescence
resonance energy transfer (FRET) mechanism, the emission spectrum of the donor must
overlap with the absorption spectrum of the acceptor (Berezin and Achilefu). In this
configuration, the transmission of the excitation energy from the donor to the acceptor
dye quenches the fluorescence of the donor (Berezin and Achilefu) decreasing the
donor’s fluorescence intensity and lifetime (M. Solomon, K. Guo, et al.). Upon
15

enzymatic cleavage, the two fluorophores separates from each other, resulting in increase
of donor’s fluorescence intensity and lifetime (M. Solomon, K. Guo, et al.). The amount
of energy transfer measured from the fluorescence intensity and fluorescence lifetime of
the activatable optical probes can be used to investigate changes in biological processes
(Berezin, Lee, Akers, Guo, et al.). Figure 1.2 illustrates the process of FRET probes
activation and application in tumor imaging. A number of FRET probes including those
optically active in NIR were designed to recover fluorescence after releasing the
quencher moiety, which occurs when the probe binds to the active site of diagnostic
enzymes (Choe, Konecky, et al.; McIntyre and Matrisian "Molecular Imaging of
Proteolytic Activity in Cancer"; McIntyre and Matrisian "Optical Proteolytic Beacons for
in Vivo Detection of Matrix Metalloproteinase Activity"; McIntyre, Scherer and
Matrisian; Z. Zhang et al.; Paulick and Bogyo).
Abnormally high proteolytic activities of extracellular and intracellular proteases
such as matrix metalloprotease (MMP), cathespin and caspase families are found to
mediate tumor growth, invasion, and metastasis (Himelstein et al.; McIntyre and
Matrisian "Molecular Imaging of Proteolytic Activity in Cancer"; McIntyre and Matrisian
"Optical Proteolytic Beacons for in Vivo Detection of Matrix Metalloproteinase
Activity"; Fingleton). Particularly, MMPs and cathespin families are involved in basement
membrane degradation, leading to local cell invasion and metastasis (Bremer, Tung and
Weissleder). The utility of the protease activatable probes for in vivo tumor imaging was
first demonstrated by Weissleder et al. (Weissleder et al.). They developed activatable
NIR fluorescent molecular probe to localize lung tumor and image the expression and
activity of lysosomal proteases. Bremer et al. used this strategy to image the expression
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and activity of MMP-2 enzymes in vivo (Bremer, Tung and Weissleder). The study
showed recovery of fluorescence after injection of the probe in mice bearing MMP-2
positive human fibrosarcomas. Fluorescence signal from the non-specific control
molecular probe was minimal. These and other activatable molecular probes have
improved the detection sensitivity of tumors in animal models.
In addition to MMPs, other biomarkers have also been targeted as tumor reporters
and for monitoring treatment responses. For example, Blum et al. developed molecular
probes that could monitor cathepsin B activity (Blum et al.), which mediates tumor
invasion and Gocheva et al. utilized fluorogenic peptides for neo-angiogenesis detection
(Gocheva et al.). These studies were conducted with in vivo mouse models of human
epithelial adenocarcinoma and pancreatic islet cell carcinogenesis respectively.
Another area of intense research is to monitor treatment response through cell
death using activatable probes. Programmed cell death, known as apoptosis, is partly
controlled by intracellular caspases. These enzymes are up regulated in cells undergoing
apoptosis and studies have shown that disruption of apoptosis results in abnormal cell
proliferation and tumor growth. The activities of these proteolytic enzymes have been
recognized as important markers for developing imaging and therapeutic agents to noninvasively monitor tumor progress and therapy response (Odonkor and Achilefu
"Differential Activity of Caspase-3 Regulates Susceptibility of Lung and Breast Tumor
Cell Lines to Paclitaxel"; Odonkor and Achilefu "Modulation of Effector Caspase
Cleavage Determines Response of Breast and Lung Tumor Cell Lines to
Chemotherapy"; Z. Zhang et al.). For instance, Bullok et al. developed FRET based
caspase activatable molecular probe, TcapQ647, composed of fluorescent moiety in
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close proximity to NIR fluorescent quencher linked with caspase cleavable peptide
sequence (Bullok and Piwnica-Worms; Bullok et al.). The study demonstrated the utility
of TcapQ647 for imaging amoeba induced cell death in mice with colon xenografts.
They observed a greater increase in parasite-infected xenografts vs. the control after
TcapQ647 injection, thus, demonstrating the potential of the compound for monitoring
treatment response. An example of caspase-3 activatable probes that are based on FRET
between two NIR cyanine dyes connected with caspase-3 cleavable peptide substrate,
Asp-Glu-Val-Asp (DEVD), was designed by Zhang et al. (Z. Zhang et al.). Upon contact
with caspase-3whose over-expression was induced by the administration of the
chemotherapeutic drug (paclitaxel) to A549 tumor bearing mice, cleavage of the DEVD
peptide sequence in the fluorescence-quenched probe resulted in the fluorescence
restoration.
Although activatable molecular probes have improved the detection sensitivity of
tumors in vivo by lowering background fluorescence, they suffer from nonspecific
activation in the blood and healthy tissues. Therefore, the development of highly
sensitive and specific activatable molecular probes for tumor imaging is an active area of
current research endeavors. Efforts to translate some of the probes to humans have
been initiated by different research groups.
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Figure 1.2: Schematic design of targeting non-activatable optical probe (top) and the
process of utilizing targeted activatable FRET probe (bottom). Step 1: Internalization of
protease activatable molecular probe via a membrane receptor. Step 2: Transmission of
the excitation energy from the donor to the acceptor dye quenches the fluorescence of
the donor. Step 3 and 4: Recovering of fluorescence after releasing the quencher moiety
when the probe binds to the active site of diagnostic enzymes.
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1.3

Hardware and Image Reconstruction
Based on the light illumination schemes, optical imaging systems are classified as

continuous wave (CW), frequency domain (FD), and time domain (TD) imaging
methods with planar, reflectance, or cylindrical modes of measurements (Gibson,
Hebden and Arridge; Wang and Wu; Erickson and Godavarty; Vo-Dinh; Xu and
Povoski; Tuchin; Hebden, Arridge and Delpy). CW optical imaging platform illuminates
tissues with light of constant amplitude or low frequency modulation and detect the light
attenuation caused by differential changes associated with the tissue absorption
properties. FD imaging platform modulates the light sources at frequencies of tens to
hundreds of megahertz and measures the amplitude decay and phase shift of the output
light to quantify tissue absorption and scattering properties. TD optical platform detects
the temporal distribution of diffuse light (photons) after illuminating the tissue with
short light pulses for depth-resolved quantification of the tissue’s absorption and
scattering properties (Chance et al.; Grosenick et al.; S. Patwardhan et al.). Hybrid
imaging methods that utilize light as part of imaging signal generation also use
tomographic approaches. For example, in photoacoustic methods, pulsed light is used to
generate ultrasound waves from local tissue's thermal expansion following light
absorption (Xu and Wang). Each of these techniques will be described in more details
below. Representative advantages and limitations of the above techniques are
summarized in Table 1.1.
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Continous Wave
Faster than TD and FD
Accurate for differential
measurement of optical
properties

Time Domain

Frequency Domain

Quantitative

Quantitative

High spatial and depth

High spatial and depth

resolution

resolution

Recovery of absorption,
Relatively compact

fluorescence, and scattering

Faster than TD but less

properties from temporal

accurate

impulse response
Recovery of absorption,
Less expensive than TD

Accurate than FD but

fluorescence, and scattering

and FD

slower

properties from diffusive
wave phase and amplitude

Table 1.1: Comparison of imaging systems techniques.
Reconstruction of optical images requires an understanding of the propagation of
light in tissue and is largely based on the knowledge of tissue properties that affect
photons and the mathematical algorithms to analyze and classify spectral data. These
algorithms help to overcome the tissue’s high spatial heterogeneity and identify small
differences between normal and cancerous tissues. Reconstruction procedure starts from
multiple measurements, where an array of light sources and detectors for a defined
geometry are used to generate and detect light. Acquisition of experimental data is
followed by the application of a light transport model. This model is based on the
propagation of photons in the region of interest. It describes the relationship between
tissue optical properties (usually absorption and scattering coefficients) associated with
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the relevant pixels and the resulting source-detector measurements (Arridge and
Schotland; Arridge; Arridge and Hebden; Arridge and Schweiger; Dehghani et al.). Light
transport in biological tissue is typically modeled stochastically by deriving probability
functions for photon transitions (Monte Carlo, random walk theory) (Wang, Jacques and
Zheng) or deterministically by deriving the diffusion equation from radiative transfer
equation (RTE) (Patterson, Chance and Wilson; Arridge and Hebden; Dehghani et al.;
Gibson and Dehghani; Wang and Wu). The first method produces more accurate results
but it is computationally demanding. Data analysis can range from several hours to
several days of computing. The method based on diffusion equation is faster. Therefore
it is used more frequently in clinical setting (Schweiger et al.). In both methods, light
transport model yields a set of dynamic equations describing the transport of photons as
a function of optical properties of the tissue and instrument setting.
After establishing the light transport model, the second step in image reconstruction
involves finding a solution to a forward problem (Arridge and Hebden; Gibson, Hebden
and Arridge; Dehghani et al.; Arridge and Schweiger; Arridge and Schotland). The
forward problem calculates the optical properties of the tissue (absorbance, scattering, or
changes in absorption or light attenuation, e.t.c.) as a result of the applied light transport
model from step one. Numerical models are commonly used to solve the forward
problem and to predict the relationship between the optical parameters for all pixels as a
function of the source-detector arrangement. Linear approximations to numerical
methods are frequently used to simplify the estimation process (Schweiger et al.; Arridge;
Gaudette et al.). The output of the forward problem is typically presented as a sensitivity
matrix, where the values obtained from the forward problem are stored.
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In the last step, the image is reconstructed by inverting the sensitivity matrix and
solving the inverse problem to recover the optical properties of the tissue (Dehghani et
al.; Arridge and Schotland; Gibson and Dehghani; Schweiger, Gibson and Arridge). To
accomplish this goal, the optimization equation is solved to recover the optical
properties of the tissue. The procedure is usually based on a least-squares equation
(linear or non-linear) expressing the difference between the measured data and the
expected measurements obtained from forward problem solution (Yalavarthy, Pogue, et
al.; Yalavarthy, Lynch, et al.). This last step has a number of challenges. In general, the
inversion of the matrix and the inverse problem solution is ill-posed because large
changes in the model tend to produce only small changes in measurable parameters (real
experimental data). Moreover, with the number of pixels larger than the number of
measurements, the problem is underdetermined (Boas et al.). Both problems can be
resolved with additional parameters known as penalty terms. These terms are added to
the least-squares equation restricting the solution and enhancing the image. Basic
Tikhonov zero-order regularization (Correia et al.) and more complex functions such as
truncated singular value decomposition (TSVD) have been implemented to improve the
image quality (Schweiger, Arridge and Nissila; Gaudette et al.; Yalavarthy, Lynch, et al.).
The search for the appropriate regularization is in progress in the field of image
reconstruction. For detailed information on light transport modeling and image
processing, the reader is referred to several extensive reviews on the subject (Arridge and
Hebden; Gibson, Hebden and Arridge). The details of the light modeling and
reconstruction algorithm implemented on this thesis will be described on each chapter as
needed.
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1.3.1

Optical Imaging Platforms

This section covers the basic principles of some optical imaging techniques such as
planar imaging; diffuse optical spectroscopy, and diffuse optical imaging, with and
without the use of exogenous contrast reagents. The roles of these techniques in clinical
detection, staging, and treatment monitoring of tumors are briefly described.

1.3.1.1 Planar Imaging
Over the past two decades, optical molecular imaging have benefited from the rapid
advances in light sources, detectors, and mathematical modeling techniques.
Fluorescence planar imaging is the simplest optical method and it is akin to flash
photography. The method is fast and affordable and data analysis is straight forward.
The light source required for planar imaging can be as simple as a single white light or a
bundle of optical fibers equipped with optical switches (Ntziachristos, Turner, et al.). In
its simplest form, appropriate filters are used to select the desired excitation wavelengths
from a broad spectrum of light source such as bright light bulbs. More recent versions
use CW lasers or light emitting diodes (LEDs) as the light source to provide higher
power for deep tissue imaging. The ensuing fluorescence is captured with a chargecoupled device (CCD) camera, the signal is recorded temporally on a computer and
displayed on a monitor in near real-time. Planar imaging systems are mostly used to
obtain two-dimensional images of tissue in reflectance (epi-fluorescence) or transmission
geometry. In transmission geometry, the detector is placed on the opposite side of the
excitation source. Most of the commercially available small animal planar imagers utilize
the epi-fluorescence mode because of its simplicity and to overcome problems with
attenuation of light in thick tissue.
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Normally, the images are generated from the recorded intensity of the emitted light
in every pixel of the region-of-interest (ROI). Such images show the location of the
target fluorescent molecular probe in tissue. However, the images are surface-weighted,
resulting in the loss of quantitative accuracy, depth information and poor spatial
resolution caused by scattering of the emitted light. Improvement of the reflectance and
trans-illumination planar imaging methods can be achieved with data normalization
approach (Ntziachristos, Turner, et al.). In this technique, the excitation and emission
light intensities are acquired sequentially by switching the interference filter between
excitation and emission scans. The normalized image is generated by simply dividing the
emission light intensity by the excitation light intensity. The phantom and in vivo studies
showed that the normalized data improved the image quality and accuracy as well as the
depth sensitivity over non-normalized method (Hyde et al.; Ntziachristos, Bremer and
Weissleder;

Ntziachristos

and

Weissleder

"Experimental

Three-Dimensional

Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born
Approximation").
Further improvement in the depth resolution of planar imaging can be achieved by
introducing phase profilometry technique into the system. The basic principle of phase
surface profile characterization (profilometry) is similar to that of tomographic imaging
systems. Both techniques have depth-sectioning ability from the recovered depth
information of the imaging object. Implementation of the phase information recovered
from the reflected light for 3D image reconstruction was first implemented by Gabor et
al. (Gabor). In this method, a spatially modulated intensity sine wave is projected onto
the object and imaged with a camera from an offset position (Srinivasan, Liu and
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Halioua). The longitudinal distance between a reference plane and the object surface is
extracted from the phase distribution at each pixel from multiple sine waves to provide
the depth information (Gioux et al.). An alternative approach is to perform a fast Fourier
transform using a single intensity sine wave (Takeda and Mutoh). In a typical
arrangement, a light source (profilometer laser) and a detector (profilometer camera) are
used to create a phase shift. The laser and camera can be synchronized by tilting the
platform to further enhance light penetration depth (Gioux et al.). Overall, profilometry
and triangulation methods produce good quality 3D images but this comes at the
expense of complex hardware and longer processing time. From instrumentation and
data analysis point of view, these techniques are closer to tomographic systems than to
conventional planar imagers.

1.3.1.2 Diffuse Optical Spectroscopy
Diffuse Optical Spectroscopy (DOS) is the most established optical imaging
technique for clinical applications. DOS has been widely used to obtain spectrally
dependent functional and structural information by extracting absorption and scattering
coefficients associated with concentration changes in endogenous and exogenous
fluorophores (Ramanujam et al.; Richards-Kortum and Sevick-Muraca; Sokolov, Follen
and Richards-Kortum; Tromberg et al.; Kukreti, Cerussi, Tanamai, et al.; Vishwanath,
Klein, et al.). Measurement of hemoglobin absorption in vivo is one of the central
approaches in DOS. The absorption spectra of oxy- and deoxy- hemoglobin state differ
significantly and the ratio between the two states in tissues is highly conserved. The
changes in oxy- and deoxy-hemoglobin concentration often indicate tissue abnormality
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and are frequently used to identify physiological problems and follow effects of therapy.
In a typical setting, DOS systems are mostly composed of a handheld probe employing a
flexible fiber based source-detector configuration. Among a variety of DOS techniques,
double-differential spectroscopic analysis and diffuse reflectance spectroscopy are the
most common. Double-differential spectroscopic analysis of tissue’s absorption and
scattering spectra from 650nm to 1000nm has been applied to discriminate normal from
cancerous breast tissues. In this method, subtracting the major absorbers' spectral
components of normal from cancerous tissues provides patient-specific molecular
signature of the tumor (Kukreti, Cerussi, Tromberg, et al.; Kukreti, Cerussi, Tanamai, et
al.).
The feasibility of diagnosing tumors and using diffuse reflectance spectroscopy to
monitor cancer therapy response by quantifying the associated physiological and
morphological changes has also been demonstrated (Vishwanath, Yuan, et al.). To
accomplish this goal, the authors extracted the concentration of oxy- and deoxyhemoglobin, and scattering coefficient by applying inverse Monte Carlo model of light
transport to diffuse reflectance spectra collected from tumor bearing mice models
(Vishwanath, Yuan, et al.). A significant increase in the concentration of oxy-hemoglobin
was observed in doxorubicin treated animals, which implies that diffuse reflectance
spectroscopy can be used to monitor treatment response non-invasively.
Palmer et al. utilized hemoglobin based DOS to study physiological changes in
response to combinational therapy using hyperthermia and liposomal doxorubicin in a
murine model (Palmer et al.). Both diffuse reflectance and fluorescence spectroscopic
measurements were performed, allowing multiparametric quantification of optical
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properties of tissues and fluorescence of the drug doxorubicin. The study demonstrated
that the total hemoglobin saturation increased after treatment. In a human study, Cerussi
et al. used DOS to evaluate a patient suffering from infiltrating ductal carcinoma (Cerussi
et al.). Here, the patient received a neoadjuvant chemotherapy consisting of

anthracyclines and bevacizumab treatments. Instead of directly comparing the tumor
water content and deoxy-hemoglobin concentration, a composite tissue optical index,
defined as ([deoxy-hemoglobin]x[water])/[lipids] was used to evaluate responses. A
decrease of ~50% in the index was found in the course of the chemotherapy, indicating
high sensitivity of the index to tumors responding to treatment.
Overall, the results obtained by different research groups demonstrate the capability
of DOS to dynamically monitor tumor-associated physiological and morphological
changes non-invasively and use the information to identify patients’ response, or lack
thereof, to chemotherapy (Choe, Corlu, et al.; Choe, Konecky, et al.; Kukreti, Cerussi,
Tromberg, et al.; Kukreti, Cerussi, Tanamai, et al.).

1.3.1.3 Diffuse Optical Imaging
Diffuse optical imaging (DOI) method is similar to DOS, but it is more complex
due to the use of multiple source-detector combinations for data acquisition and image
reconstruction. DOI has been used successfully in a quantitative study of the
pharmacokinetics and pharmacodynamics of diagnostic and therapeutic agent, which is
also the basis for this thesis work (S. Patwardhan et al.; S. V. Patwardhan, S. Bloch, et al.;
Patwardhan and Culver; Ntziachristos, Tung, et al.; Choe, Konecky, et al.; Hebden,
Arridge and Delpy).
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Diffuse optical tomography (DOT) method produce three-dimensional images of
tissue by combining measurements from multiple sources and detectors with light
diffusion modeling techniques for depth localization (Vo-Dinh; Gibson, Hebden and
Arridge; Wang and Wu; Hebden, Arridge and Delpy). A variant of DOI systems,
fluorescence molecular tomography (FMT), acquires excitation and emission light
intensity profiles sequentially with interference filter switching between two scans
(Ntziachristos, Bremer and Weissleder; Ntziachristos, Tung, et al.; Pogue, Gibbs, et al.).
A CCD camera is generally used as detector in this technique. The sequentially acquired
excitation and emission light intensities are used to generate normalized data-set from
the emission light intensity profile divided by the excitation light for volumetric
reconstruction of the fluorescence distribution. Using this approach, Patwardhan et al.
developed an FMT system capable of whole-body small animal imaging within a few
minutes (S. Patwardhan et al.). The system was successfully used to quantify the
biodistribution of targeted fluorescent molecular probes in mice bearing subcutaneously
implanted human breast carcinoma.
In addition to reporting the fluorescence intensity, optical imaging systems can be
modified to quantify fluorescence lifetime. Fluorescence lifetime is an intrinsic property
of endogenous and exogenous fluorophores that relates to the average time a
fluorophore remains in the excited state before light emission. Advances in laser
technology and instrumentation have led to the development of time-resolved imaging
techniques for whole-body imaging of cancer in small animal. This trend has aided the
growing interest in developing new FLI systems for tumor imaging (Berezin, Lee, Akers,
Guo, et al.; Nothdurft et al.; Bloch et al.; Berezin and Achilefu).
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An important advantage of fluorescence lifetime contrast over fluorescence intensity
measurements lies in its less dependence on the fluorophore concentration. However, it
is generally sensitive to changes in the local tissue environment such as pH, temperature,
and presence of fluorescence quenchers (Berezin, Lee, Akers, Guo, et al.; Nothdurft et
al.; Bloch et al.; Berezin, Lee, Akers, Nikiforovich, et al.). This sensitivity to differences
in tissue composition and biochemistry has been used to differentiate cancerous from
normal tissues by fluorescence lifetime imaging (FLI) (Berezin, Lee, Akers, Guo, et al.;
Nothdurft et al.; Bloch et al.; Berezin and Achilefu). Cubeddu et al. applied time-domain
imaging to localize tumors after fluorescent hematoporphyrin derivative (HpD) uptake
used for photodynamic therapy (Cubeddu, Canti, Taroni, et al.; Cubeddu, Canti, Pifferi,
et al.). The authors treated L1210 leukemia and fibrosarcoma tumors with
hematoporphyrin derivative and observed that the fluorescence lifetime were longer in
both tumors than in the surrounding normal tissue. This group also demonstrated that
FLI can discriminate between normal and basal cell carcinoma in human skin based on
the lifetime differences between protoporphrin IX and normal tissue autofluorescence
(Andersson-Engels et al.).
Reynolds et al. used frequency domain for lifetime sensitive detection of molecular
probes. They extracted and differentiated NIR contrast agents based on their lifetime
differences in tissue mimicking phantoms (Reynolds et al.). The ability to measure
multiple fluorescence lifetimes from several fluorescent probes in relatively narrow
lifetime range (0.5-1.2 ns) demonstrated the potential of fluorescence lifetime imaging in
differentiating cancerous from normal tissues. Most in vivo lifetime imaging studies were
confined to specialized laboratories until the commercialization of a time-domain
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lifetime imaging system. Bloch et al. demonstrated the feasibility of using receptortargeted NIR fluorescence molecular probe (cypate-GRD) for non-invasive whole-body
fluorescence lifetime imaging with this commercial system (Bloch et al.). The study
showed selective localization of the tumor based on the probe’s lifetime properties.
Further tissue analysis showed that the fluorescence lifetime of the molecular probe was
1.03 ns in tumor and 0.83 ns in the surrounding tissue. Although the lifetime changes
appear to be small, modern FLI systems are capable of resolving 0.1 ns lifetimes, making
it possible to potentially detect small but significant physiological changes in tumors.
The development of fluorescence lifetime tomography has further enabled
improved temporal resolution and accurate tissue localization up to 1 cm depth of
targeted tumor using fluorescent molecular probes. Nothdurft et al. developed a
fluorescence lifetime tomography system that quantitatively resolves fluorescence
lifetimes within the narrow range 0.35 ns and 1.35 ns in vivo (Nothdurft et al.). In this
work, targeted exogenous NIR optical probe, cypate-cyclic[RGDfk], was injected into a
mammary carcinoma mouse model and the fluorescence lifetime map of whole animal
recorded. The tumor was quantitatively differentiated from the surrounding tissue based
on the fluorescence lifetime and intensity maps.
Fluorescence lifetime imaging has also enabled imaging of multiple fluorophores
with similar absorption and emission spectra but different lifetimes to provide
simultaneous information about specific molecular processes without the need for
spectral deconvolution of each fluorophore. Reynolds et al. [69], Akers et al. (Akers et
al.) and Raymond et al. (Raymond et al.) were able to recover and separate the
distribution of two or/and three NIR fluorescent probes that localized in different
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organs of mice based on difference of their lifetimes. Their findings suggest that the
fluorescence lifetime of different molecular probes can be multiplexed to monitor a
variety of molecular interactions through a careful design of NIR fluorescent probes to
exhibit lifetime shifts upon target binding. However, one should keep in mind that the
difference between individual fluorescence lifetimes must surpass the temporal
resolution of the instrument (currently ~100 ps for tomographic systems) to realize
lifetime multiplexing.
Overall, optical molecular imaging has the potential to become a powerful and
practical tool for a wide array of applications such as noninvasive early detection, imageguided biopsies and intraoperative procedures, and therapeutic monitoring of cancer.
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Chapter 2
Video-rate Fluorescence Diffuse Optical
Tomography for in vivo Sentinel Lymph
Node Imaging
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2.1

Introduction
Sentinel lymph node biopsy (SLNB) is the current standard procedure used for

prognostic staging of cancers and therapeutic guidance. SLNB is a minimally-invasive
procedure that involves the removal of sentinel nodes (the first lymph nodes that receive
drainage from the primary tumor) for nodal staging. The location of sentinel lymph
nodes (SLNs) is routinely determined by injecting radioactive lymphophilic tracer dye
intra-operatively around the tumor region. The lymphophilic tracer is commonly
composed of a radioactive colloid and/or optical contrast methylene blue for visual
guidance (Tuttle et al.; Hojo et al.). Due to safety issues, a non-invasive and non-ionizing
method for imaging of metastatic lymph nodes and lymphangiogenesis would be
preferred. Fluorescence diffuse optical tomography (DOT) is an emerging deep tissue (>
3 mm) imaging technique that has great potential as an alternative to radioactive tracer
analysis for noninvasive detection and imaging of the sentinel lymph node. While
fluorescence DOT often operates on the time scales of minutes to hours, the method
also has the potential for imaging at higher speeds above the respiratory and cardiac
fluctuations, allowing it to capture pharmacokinetics and pharmacodynamics of
diagnostic and therapeutic agents.
Currently, most fluorescence diffuse optical tomography systems are CCD camerabased systems that scan at relatively slow speeds (i.e., frame rates < 0.01 Hz). The slow
speed is due in part to the method by which ratio-metric data is acquired. Excitation and
emission light intensity profiles are imaged consecutively, which requires that an
interference filter for blocking the excitation light to be mechanically inserted between
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the two scans (Ntziachristos and Weissleder "Charge-Coupled-Device Based Scanner for
Tomography of Fluorescent near-Infrared Probes in Turbid Media"; S. V. Patwardhan,
S. R. Bloch, et al.; Patwardhan and Culver). Comparison of sequentially acquired
excitation and emission light intensities improves image quality through the generation
of a normalized ratio-metric data-set (Patwardhan and Culver; Ntziachristos, Turner, et
al.). However, the mechanical requirements of sequential scanning slow data collection
and pose a challenge for real-time imaging. Alternatively, DOT systems developed to
image functional absorption contrast have used time- or frequency-encoding of the
illumination with broad spectral detection to image fast activities (> 10 Hz) within the
human brain. This style of DOT system replaces the CCD-camera acquisition with
multiple photodiode detectors in order to take advantage of the high dynamic range and
high speed of avalanche photodiodes (APDs) (Culver, Siegel, et al.; Franceschini and
Boas; Zeff et al.). However, the discrete detector DOT approach has not yet been
applied to ratio-metric data for fluorescence DOT.
Herein, we aim to improve upon current fluorescence DOT platforms by
developing a system with expanded dynamic range and faster data acquisition rates. The
video-rate, fiber-based fluorescence DOT system design is built upon a previously
published APD-based platform for high-speed DOT (Zeff et al.).
The source-detector grid is designed as a contact probe to pre-operatively identify
SLNs near the tumor region after administration of a fluorescent contrast agent. Biopsy
of SLNs would follow intra-operatively to enable further histological evaluation for the
presence of metastatic cells. These studies with a non-specific, but approved, contrast

35

agent ICG will set the stage for future work with more specific targeted contrast agents
that fluoresce/activate in the presence of metastatic cells.
Fiber-based, video-rate fluorescence DOT could additionally improve the flexibility
of imaging by adapting to varying tissue curvatures and performing simultaneous
multiple point illumination and collection, thus increasing the imaging frame rate.
In this chapter, I demonstrate the feasibility of in vivo imaging of the dynamics of
dye accumulation in the region of the sentinel lymph nodes and quantify the accuracy of
depth localization and sensitivity in tissue-simulating phantoms. These results
demonstrate that fiber-based, video-rate fluorescence DOT is a practical and powerful
tool that is well suited to a wide array of potential imaging applications, ranging from
sentinel lymph node mapping to monitoring cancer therapy progression.

2.2

Methods
The generation of ratio-metric (fluorescence-to-reference) data for fluorescence

DOT reconstructions has previously relied on sequentially acquired measurements where
the source laser is kept at the excitation frequency while a band-pass filter in front of the
detector alternates between allowing through excitation and emission (fluorescent) light.
The detected excitation light is then used as a reference to normalize the measured
fluorescence. The acquisition of such ratio-metric data allows reconstructions using the
normalized Born approximation, which can be implemented to quantify fluorochrome
distribution. However, while the use of an excitation reference is customary, it is not
required. The assumption that light at the excitation wavelength acts as a good reference
inherently assumes similar optical properties at the two wavelengths. And, if this
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assumption is made, there is no reason why light at the fluorescence wavelength could
not be used as a reference. With a CCD-based system, this would be impractical, as there
would be no way to determine the difference between the fluorescent and reference light
at the same wavelength. However, with APD-based detection, high speed allows the use
of frequency-encoding regimens to separate out contributions from different sources.
With this encoding scheme, there is no longer any need for the hardware-based
temporal-encoding of switching a filter in and out of the light beam. This paradigm is the
basis for the system presented here.
The fiber-based, video-rate fluorescence DOT system is composed of an alternating
grid of 12 sources and 13 detectors (Figure 2.1). The video-rate fluorescence DOT
system uses multimode fiber to carry light from the source box (Figure 2.1 A.1) to the
imaging pad (Figure 2.1 A.2) and then to the detector box (Figure 2.1 A.3).

Figure 2.1: Fiber-based, video-rate fluorescence DOT system setup (a) The video-rate
fluorescence DOT prototype. Fibers carry light from the source box (1) to the imaging
pad (2) then to APDs in two detector boxes (3). The detected signals are digitized by an
ADC recording unit (4). (b) A close-up of a 5x5 fiber array.
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The source channels contain 785 nm (Thorlabs DL7140-201S) (3.5 mW) and 830
nm (Thorlabs HL8325G) (0.25 mW) laser diodes, with dedicated laser diode drivers and
control lines for each source, allowing flexible software configurable source encoding
(frequency- and time-encoding) (Figure 2.2 A). Light from the sources is coupled into
2.5 mm diameter fiber bundles. The detection channels use optically-filtered discrete
avalanche photodiodes (Hamamatsu C5460-01) digitized with dedicated 24-bit analogto-digital converters (MOTU HD 192). A narrowband optical filter with center
wavelength 830 +/- 10 nm (CVI) and an out-of-band rejection of OD4 separates the
excitation light from fluorescent and reference signals. An aspheric lens is used to
collimate the light in order to optimize the blocking of excitation light by the
narrowband interference filter and enhance fluorescent signal detection. This design
provides high instantaneous dynamic range (106) and cross-talk rejection (10-6), so that
light levels can be detected over many orders of magnitude. With this scheme, we
acquire frequency-encoded fluorescence emission and reference transmission light levels
simultaneously at each detector through the individual interference filters optimized for
fluorescence emission (Figure 2.2A). All data are acquired at a frame rate of 30 Hz. A
total of 108 measurements from source-detector-pairs (also known as optode-pairs)
representing the 1st, 2nd, and 3rd nearest-neighbors are used for image reconstruction.
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Figure 2.2: Schematic of the video-rate fluorescence DOT hardware. (A) Schematic
demonstrating frequency-encoding of 830 nm and 785 nm laser diode sources. Both
reference and excitation light (at distinct frequencies) are incident on the tissue. Light
exiting consists of reference, excitation, and emission (fluorescent) light. After
collimation, the light is passed through a narrow band optical filter (F) to block the
excitation light (785 nm). The resulting detected light, a sum of the reference
transmission (I2) and fluorescence emission (I3), is simultaneously detected by a single
detector. (B) A Fourier transform of the sum of I2 and I3 provides identification of
transmission and emission signals from a single detector.

2.2.1

Ratio-metric Reconstruction

The reference transmission and fluorescent emission light intensities acquired
concurrently at each detector (Figure. 2.2B) are used to generate ratio-metric data of
fluorescence divided by reference transmission. The data are then reconstructed using
the normalized Born approach to correct for tissue and illumination inhomogeneities,
which is written in discrete notation as y=Ax with the following definitions (Zeff et al.).
!!"# !!(!) ,!!(!) ,!!"#

In the Normalized Born approach: 𝑦! =    !

!"#

!!(!) ,!!(!) ,!!"#

. When the bleed-

through of the filter is accounted for then the Normalized Born approach becomes:
𝑦! =   

𝜙!"# 𝑟!(!) , 𝑟!(!) , 𝜆!"# − 𝜙!"##$%!!"#$! (𝑟!(!) , 𝑟!(!) )
𝜙!"# 𝑟!(!) , 𝑟!(!) , 𝜆!"#

The ratio-metric data (y) is generated by measuring the fluorescence light intensity
profile 𝜙!"# 𝑟!(!) , 𝑟!(!) , 𝜆!"#

at emission wavelength,  𝜆!"# , and the reference
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transmission light intensity profile, 𝜙!"# 𝑟!(!) , 𝑟!(!) , 𝜆!"# , at the reference wavelength ,
𝜆!"# . The ith source-detector measurement (yi) is associated with source (rs(i)) and
detector (rd(i)) locations.
The bleed-through measurement is made in the absence of a fluorescing agent and
measures the amount of light leakage through the filter. It is determined by:
𝜙!"##$%!!"#$! 𝑟! ! , 𝑟!

!!"# !! ! ,!!"#
!"# !! ! ,!!"#

𝑤ℎ𝑒𝑟𝑒  𝑅 = !

! !
= 𝛼×𝜙!"# 𝑟! ! , 𝜆!"# =    𝛼!"#$%&
×𝑅×𝜙!"# 𝑟! ! , 𝜆!"# ;

!

;  

𝛼 captures the optical density of the filter. In this fiber-based fluorescence DOT system
there are individual detectors and sources, and the sources have separate lasers for both
reference and excitation. Therefore, the 𝛼 is calculated separately for each sourcedetector pairs. To calculate the bleed-through specific to an imaging study, we derived an
estimate of the bleed through of 𝜙!"# based on 𝜙!"# . Experimentally determined
conversion factors (𝛼 and R) are used to account for the difference in power level
between the excitation and reference lasers. R is measured using a power meter at source
!(!)

fiber tips of each sources and 𝛼!"#$%& is the excitation light measured with and without
filter,  𝜙!"# 𝑟! ! , 𝜆!"# , for each detectors at the excitation wavelength (𝜆!"! ) of 785 nm.
The sensitivity matrix (𝐴!,! ) is created using the analytic solutions for photon density
in the semi-infinite geometry to obtain the influence of a particular voxel j on every
source and detector measurement i.
𝐴!,! = −

𝑠! 𝑣ℎ! 𝐺 𝑟! ! , 𝑟! , 𝜆!"# 𝐺 𝑟! , 𝑟! ! , 𝜆!"#
  
;  𝑥!  ! 𝜕𝑁!
𝐷!
𝐺 𝑟! ! , 𝑟! , 𝜆!"#
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The So is calibration factor while h3 represents the voxel volume. The Do and v are
the diffusion coefficient and speed of light in the medium. The two-point Green’s
function, G, models light transport for the given boundary condition. Optical properties
at the reference wavelength of µa = 0.1 cm-1 and µs' = 10 cm-1 were used to model the
optical properties of rat and chicken muscles for both in vivo and phantom studies
(Marquez et al.; Nilsson, Berg and Andersson-Engels; Cheong, Prahl and Welch). In this
case, a semi-infinite geometry is implemented. 𝑥!   is the jth recovered image voxel that
contains the fluorescence yield,  𝜕𝑁! , obtained using a Moore-Penrose generalized inverse
(Culver, Siegel, et al.).

2.2.2

System Performance Analysis

2.2.2.1 Design of Simulation Studies
The system's depth sensitivity was first evaluated with simulation studies before
proceeding to phantom and in vivo studies. To evaluate the depth sensitivity, 1x1x1 mm
fluorescent targets mimicking labeled sentinel lymph nodes were simulated as
perturbations in homogeneous medium with the addition of 1% biological measurement
noise at different depths. A sensitivity matrix with a simulated grid of 12 sources and 13
detectors was implemented for image reconstruction. To evaluate a potential clinical
application, sentinel lymph node mapping for cancer staging, we reconstructed simulated
fluorescent lymph nodes at various depths (3, 5, 8, 11, 15,) with simulated 1% noise
(Figure. 2.3A). The reconstructed images suggest that the video-rate fluorescence DOT
will have depth-sectioning capabilities with accurate depth localization down to 15mm
confirming its potential for clinical application (Figure 2.3B). The resolution of the
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system was tested by using the simulated 1x1x1 mm target at different depths. The size
of the reconstructed perturbation is measured with the full width at half maximum
(FWHM) of each target's point-spread function (PSF). We observe a broadening of the
response with depth (Figure 2.3C).

Figure 2.3: Evaluations of imaging depth sensitivity. To evaluate the depth sensitivity of
the reflectance fluorescence DOT imaging array (Figure 2.1c), we reconstructed images
from simulated data for targets at different depths. Two-dimensional slices through a
volume show a cross-sectional view. Targets of 0.125 mL in volume (A) at the depths of
3, 5, 8, 11, 15 mm (left to right) were reconstructed. (B) Targets are all clearly visible
even in the presence of simulated measurement noise (1%). (C) Point-spread function
analysis using a simulated image reconstruction. Half-maximum contours of responses
for different depths are shown.

2.2.2.2 Design of Phantom Studies
To evaluate the performance of the system, different concentrations of ICG targets
in 3 mm diameter plastic tubes were prepared and embedded at 7 mm depth in a breast
tissue mimicking phantom with µa = 0.1 cm-1 and µ's = 10 cm-1 (Figure 2.4A). The
breast tissue simulating phantom was constructed by mixing 1% Intralipid solution with
Black India ink to obtain the appropriate absorption and scattering properties (Flock et
al.). The absorption and reduced scattering coefficients are chosen based on previously
published values of rats and chicken breast optical properties (AN. Bashkatov et al.;
Cheong, Prahl and Welch; Nilsson, Berg and Andersson-Engels; Marquez et al.). The
targets contained solutions of indocyanine green (Sigma-Aldrich, St Louis, MO) in
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concentrations ranging from 1 nM to 1 µM. The averaged values from regions-ofinterest (ROIs) of the reconstructed image were compared to known concentrations to
evaluate the sensitivity and linear response of the system.
Analysis of the system’s sensitivity as a function of depth was performed by
submerging a 3 mm diameter plastic tube of 4 µM concentration in a tissue-mimicking
phantom. Starting at a depth of 5.5 mm, the tube was moved in 1.5 mm increments via a
vertical stage until the middle of the tube reached a depth of 13.5 mm. The depth
localization accuracy of the fluorescent target and sensitivity were calculated by averaging
the intensity of the tube ROI and computing the center-of-mass for the different depths
acquired.

2.2.3

Probe Dynamics Measurement in Sentinel Lymph
Node Imaging

2.2.3.1 Design of in vivo Studies
We conducted a non-invasive preclinical study of fluorescent sentinel lymph node
mapping in rats (n=5) with our fiber-based, video-rate fluorescence DOT system. The
hair was shaved from the axillary region prior to imaging. In order to test the
translational feasibility of the system to humans (which will require imaging at depths >
1 cm), we also conducted an experiment mimicking a deeper imaging scenario than
would normally be available in a rat by inserting 8-10 mm of chicken breast tissue
between the rat chest wall and the imaging pad (Figure 2.4B). Imaging through 8-10 mm
chicken breast increased the depth of the SLNs to 10-12 mm, which is deeper than the
typical 2 mm where the SLNs are normally located below the skin surface in rats.
Control images were acquired for 1 minute prior to administration of the ICG, and the
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dynamics of the injection in the axillary region were monitored for 10 minutes
continuously.
Animal handling was performed according to the guidelines approved by the
Washington University School of Medicine Animal Studies Committee for humane care
and use of laboratory animals. For in vivo imaging, 50 µL of 100 µM ICG was injected
intradermally in the left forepaw of 200-250 g female Sprague Dawley rats (HSD,
Indianapolis, IN) after giving a mixture of ketamine (85 mg/kg) and xylazine (15 mg/kg)
for anesthesia. After imaging, rats were then euthanized with an overdose of
pentobarbital solution (150 mg/kg, IP) and the lymph nodes were then resected for
verification of ICG uptake.
For reference and verification of ex vivo ICG uptake by the lymph nodes,
superficial fluorescence images were acquired without the layers of chicken breast using
the Pearl near-infrared (NIR) fluorescence imaging system (LiCor Biosciences, Lincoln,
NE).
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Figure 2.4: Schematic of the video-rate fluorescence DOT experimental setup. (A)
Schematic of my experimental setup with an imaging array and a 3 mm ICG tube
embedded in a tissue-mimicking phantom. (B) Schematic of the placement of the fiber
array on a preclinical animal model using an 8-10 mm thick chicken breast to simulate a
deep tissue imaging situation.

2.3

Results

2.3.1

System Performance Analysis with Phantom Studies

The Fourier transform of a measurement from a single detector illustrates the use of
frequency-encoding to separate the emission and reference measurements acquired
simultaneously (Figure 2.2B). Following frequency-decoding, the intensities of both
reference transmission and emission were retrieved. The data was then used to generate
volumetric reconstructions of the fluorescence distribution. The reconstructed images
from various depths suggest that the newly developed video-rate fluorescence DOT
system has the capability to accurately section depths up to 13.5 mm (Figure 2.5B). The
resolution of the system was tested with simulated data for 1×1×1 mm phantom targets
at different depths (Figure 2.3C). The center-of-masses (COMs) of the reconstructed
fluorescence tubes (Figure 2.5B) were computed by averaging the fluorescence intensity
values for each experimental depth. The linear relationship between the experimental
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and the computed COMs demonstrate the depth localization accuracy up to 13.5 mm
(Figure 2.5C). The sensitivity as a function of depth was computed by taking the mean
fluorescence intensity of the regions-of-interest from reconstructed image for the
different depths acquired (Figure 2.5D). The data demonstrate that the signal intensity
drops exponentially with depth, as expected.
The relationship between the true dye concentration and the reconstructed voxel
value (arbitrary units), is shown in Figure 2.5E. The graph confirms the high dynamic
range and linear response of our system to varying ICG concentrations as measured by
the resulting fluorescent yield from 1 nM to 1 µM. Values from this phantom analysis are
used to generate a calibration factor for our in vivo studies.
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Figure 2.5: System sensitivity analysis with phantom studies. (A) Schematic of our
experimental setup with an imaging array and a 3 mm ICG tube embedded in a tissue
mimicking phantom. (B) Vertical x-z and y-z slices of reconstructed experimental data
from a fluorescent 3 mm tube target whose center of mass is located at 7.5 mm, 10.5
mm, and 13.5 mm depths. The system accurately reconstructs the tube shape with some
artifact at the optode positions. (C) Evaluation of the depth localization accuracy of a
phantom target. The system has accurate localization from 6 to 13.5 mm. (D) Sensitivity
vs. depth. The data demonstrate that the signal intensity falls off exponentially with
depth. (E) The relation between the raw reconstructed value and the true concentration
of the dye was characterized by titration of ICG from 1 nM to 1 uM concentrations in a
3 mm tube.
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2.3.2

In vivo Imaging of the Uptake of the dye into SLNs

We performed a pre-clinical in vivo study to evaluate the feasibility of imaging
sentinel lymph nodes in rats noninvasively. ICG was injected intradermally into the
forepaw and the axillary region was imaged with DOT. The DOT images of fluorescent
lymph dynamics shown at 2 mm were obtained following injection of the ICG (Figure
2.6A). Representative dynamics of fluorescent lymphatic fluid accumulation is obtained
from a volume of about 30 mm3 from the region of the sentinel lymph node of the
injection site (Figure 2.6B). The mean of the background pixels shows no fluctuation
associated with the dynamics of fluorescent dye.
Reflectance fluorescence images were captured using the Pearl NIR fluorescence
imaging system before sacrificing the animal to confirm the DOT results (Figure 2.6C).
Reflectance fluorescence images acquired after euthanasia and removal of overlying skin
further confirmed ICG uptake by the lymph node imaged by DOT (inset on Figure
2.6D).
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Figure 2.6: Shallow imaging of lymph dynamics. (A) DOT images of the fluorescence
dynamics at 2 mm depth in a rat following injection of ICG into the left forepaw. (B)
Time traces of the dynamics of ICG accumulation in the region of the sentinel lymph
node (for comparison the mean background signal is shown). (C) Reflectance
fluorescent imaging of the sentinel lymph node region demonstrating fluorescence from
the injection site (paws) and the lymph vessels leading to axillary lymph nodes (arrow).
(D) Reflectance fluorescent image of the rat after euthanasia and removal of overlying
skin. Inset: fluorescence from ex vivo imaging shows ICG uptake in the lymph nodes.
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We repeated the experiment with an increased imaging depth by inserting 8-10 mm
of chicken breast between the rats (n=5) and the imaging pad. DOT images of
fluorescent lymph dynamics were acquired and show that high quality imaging can be
obtained even at increased depth (Figure 2.7A). Time courses of the SLN region as well
as background pixels demonstrate the representative dynamics of fluorescent lymphatic
fluid accumulation after the injection (in two individual rats Figure 2.7B and averaged
over all five rats Figure 2.7C). The variability in the lymph dynamics and accumulation in
the SLNs can be associated with inter- and intra-subject variability of the periodic
expansion and contraction structures that surrounds the lymphatic vessels. The results
demonstrate the potential of the video-rate fluorescence DOT system to image the in
vivo dynamics of dye accumulation in SLNs.
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Figure 2.7: Deep (> 10 mm) imaging of lymph dynamics. The video rate fluorescence
DOT was used to image the SLN region in rats through 8-10 mm of chicken breast
following ICG injection into the rat forepaw. (A) The dynamics in a slice at 11 mm
depth from a DOT reconstruction. (B) Time traces of the dynamics (for 2 representative
rats) of a region around the SLN and of the mean of all background pixels. (C)
Dynamics of ICG accumulation averaged over 5 rats.
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2.4

Discussion
Fiber-based, video-rate fluorescence DOT has the potential to become a powerful

and practical tool for a broad array of imaging applications, ranging from sentinel lymph
node mapping to monitoring cancer therapy progress. We demonstrated the feasibility of
a 30 Hz APD-based fluorescence DOT system. Images of fluorescent targets in tissue
mimicking phantoms were used to confirm the high dynamic range and linear response
of the system and the accurate localization of targets in the range of depths from 5.5 to
13.5 mm. As the optical properties used in our experiments are higher than those
reported for human breast tissues we expect the depth sensitivity and dynamic range to
be improved in human studies.
We also successfully demonstrated the in vivo capabilities of the system by
noninvasively imaging the dynamics of ICG accumulation in a rat. Accumulated dye in
the region of the sentinel lymph nodes was imaged to a depth of 10-12 mm over a 10
minutes time course. These results demonstrate the potential for imaging the
pharmacokinetics of fluorescent diagnostic and therapeutic agents.
Previous two-dimensional fluorescence reflectance imaging (FRI) has been used to
image lymph nodes and the lymphatic systems in animal models and cancer patients
(Frangioni et al.; Proulx et al.; Sharma, Wang, et al.; Sevick-Muraca et al.; Troyan et al.;
Sampath, Wang and Sevick-Muraca; Sharma, Wendt, et al.). For instance, the lymph
dynamics and lymph node images obtained after injection of ICG in breast cancer
patients show the feasibility of implementing FRI for nodal staging (Sevick-Muraca et
al.). The specificity of the FRI method was further evaluated with an intraoperative FRI
system by localizing the same SLNs as lymphoscintigraphy in breast cancer patients
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(Troyan et al.). This particular FRI system is currently on clinical trials for intraoperative
SLN mapping in cancer patients (Frangioni et al.; B. T. Lee et al.; Proulx et al.; Troyan et
al.). While the FRI method is useful, its sensitivity declines quickly with imaging depth.
Three-dimensional DOT methods address several limitations of FRI and can
potentially improve deep-tissue sensitivity, volumetric localization, resolution, and
quantitative accuracy. For example, DOT approaches have been used in small animals to
image whole bodies (Intes, Ntziachristos, et al.; S. V. Patwardhan, S. R. Bloch, et al.) and
in humans to image breast (Pogue, Poplack, et al.; Culver, Choe, et al.; Choe, Corlu, et
al.; Q. Zhang et al.) and brain (Joseph et al.; Austin et al.) tissues at depths of several
centimeters. One limitation of our current system for application in humans is the
limited field of view. The potential for an expanded system with up to 48 sources and 48
detectors has been demonstrated for brain imaging (White et al.). A higher density
imaging array could also potentially increase the resolution, particularly at the shallower
depths (Culver, Ntziachristos, et al.).
Sentinel lymph node localization is currently performed by administering
radiocolloids conjugated with blue dye for intraoperative guidance (Rzyman et al.). The
potential of implementing other organic optical dyes such as fluorescein and indocyanine
green has also been demonstrated in multiple clinical trials (Sampath, Wang and SevickMuraca; Sevick-Muraca et al.; Troyan et al.; Hojo et al.; B. T. Lee et al.; Proulx et al.).
Extensive research is still needed into targeted optical dyes. Fiber-based, video-rate
fluorescence DOT aided with targeted optical dyes could have the potential to assess the
cancer status of SLNs non-invasively in order to avoid unnecessary surgical procedures.
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Multimodal imaging with fluorescence DOT could also play an important role in the
detection and imaging of sentinel lymph nodes for cancer management. DOT could be
combined with, for example, nuclear imaging to improve the accuracy of DOT images
during data processing and image reconstruction (Cao and Peter; A. Li et al.; Barber et
al.). In addition to a standalone mode (and due to the flexibility of the fiber array
geometries), video-rate fluorescence DOT also has the potential to be combined with
handheld ultrasound (US) and/or photoacoustic tomography (PAT). Fibers assembled
around the periphery of the PAT/US imaging head could provide many tracings through
the PAT/US imaging volume. A similar approach wherein DOT is combined with
ultrasound has been demonstrated feasible for imaging breast cancer (Q. Zhu et al.;
Quing Zhu et al.). In these scenarios, the fluorescence molecular contrast of DOT would
complement the high-resolution function and anatomical data of PAT and US.

2.5

Conclusion
In this chapter, we have shown we have developed a fiber-based, video-rate

fluorescence DOT system and demonstrated its potential for in vivo imaging. We have
demonstrated that a 30 Hz APD-based DOT system can be operated in fluorescence
mode. A fiber-based imaging array was used to image a fluorescent target within a tissuemimicking phantom and to exhibit our system’s high sensitivity. These results confirmed
the high dynamic range and linear response of the system. We have also successfully
demonstrated the capability of the system for sentinel lymph node mapping in rats.
Further progress with this technology has the potential to provide a useful clinical tool
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for a wide array of imaging applications, ranging from sentinel lymph node mapping to
monitoring cancer therapy progress.
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Chapter 3
Multimodal Fluorescence Mediated
Tomography and SPECT/CT for Small
Animals Imaging
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3.1

Introduction
Multimodal imaging strives to improve upon uni-modal imaging by combining

multiple contrasts. For example, combining anatomical and molecular imaging (PET/CT
and SPECT/CT) has provided an anatomical context for the detailed molecular
information from the nuclear contrasts (Quing Zhu et al.; Alberini et al.; Even-Sapir,
Keidar and Bar-Shalom). However, full fusion of the anatomical and molecular
information is limited by the relatively weak connection between the different contrasts.
Alternatively multiple molecular contrasts might be joined through specific links (S.
Achilefu, Y. P. Ye, et al.; Zhang and Achilefu). For example, optical methods have
unique activation contrast mechanisms, which are complementary to PET/SPECT
information. The information available to both nuclear and optical contrasts can be
harnessed directly using monomolecular multimodal imaging agent (MOMIA) (S.
Achilefu, Y. P. Ye, et al.; Zhang and Achilefu). Imaging of MOMIA agents requires
suitable instrumentation and algorithms. To combine optical data with PET/SPECT,
optical contrasts can be imaged in three dimensions by diffuse optical tomography
(DOT) (Z. R. Zhang et al.; Cao and Peter; Culver, Akers and Achilefu; C. Q. Li et al.). In
this chapter, we demonstrate the feasibility of combining the previously reported fiberbased, video-rate fluorescence mediated tomography (FMT) system (Metasebya Solomon
et al.) with a preclinical NanoSPECT/CT platform (Bioscan, Inc.) for combined optical
and nuclear imaging of dynamic events associated with lymphatic transport.
The design and construction of a multimodal imaging platform presents a number
of challenges. The first is integrating hardware such that each modality can function with
minimal, or acceptable, interference from the others. Hardware integration requires
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compatibility of all the parts for both platforms. The second challenge is spatial and
temporal co-registration of information from the disparate reporting strategies under
each modality. For instance, the distinct chemical and physical characteristics of
traditional contrast agents might lead to different biodistribution and migration rates.
MOMIAs are being developed to address these pharmacokinetic issues. Recent work has
demonstrated the use of this approach for SPECT/optical (H. Lee et al.; Q. Zhang et
al.), PET/Optical (Berezin, Guo, Teng, et al.; Zhang and Achilefu), and MRI/optical
(Gulsen et al.; Guo et al.; Ntziachristos, Yodh, et al.) imaging. The last challenge is
determining how to merge the anatomical or functional information from multiple
technologies into a single imaging output. This is currently a subject of intensive
research, though most of the work is focused on incorporating structural information
from X-ray/CT (Ntziachristos, Yodh, et al.; Culver, Akers and Achilefu; Q. Zhang et al.)
or MRI (Q. Zhang et al.; Gulsen et al.) with molecular imaging. Merging information
that leverages the respective strengths of each modality would provide new insight into
biological processes relevant to cancer diagnosis and therapy monitoring (S. Achilefu, Y.
P. Ye, et al.; Culver, Akers and Achilefu).
To address the instrument integration challenges, we took advantage of the
flexibility of fiber arrays to provide a compact conduit of light to and from the animal so
that the FMT imaging array could fit into the bore of the existing NanoSPECT/CT
system without modifications. In addition, to facilitate integration of the nuclear and
optical contrasts, we used a MOMIA based on a radiolabeled near-infrared dye
synthesized in our laboratory (Zhang and Achilefu).
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Feasibility studies of simultaneous fluorescence and radioactive imaging were
performed in tissue simulating phantoms and in vivo in rats. Accurate depth localization
of the MOMIA targets was established to depths of up to 10 mm. Fluorescence and
radioactivity from an injection of MOMIA into the forepaw region was imaged over
time to follow the lymphatic dynamics. These studies were used to assess whether the
proposed combined multimodal platform has the potential to become a practical tool for
a broad array of imaging applications, ranging from early disease detection to monitoring
progress of disease and therapies.

3.2

Materials and Methods

3.2.1

Fiber-based FMT Imaging System

DOT source and detector console: Laser diodes with a wavelength of 785 nm
(Thorlabs DL7140-201S) (3.5 mW) and 830 nm (Thorlabs HL8325G) (1.5 mW) have
dedicated drivers and control lines for each source to allow flexible software
configurable source encoding (frequency- and time- encoding). The detection channels
use optically-filtered discrete avalanche photodiodes (Hamamatsu C5460-01) digitized
with dedicated 24-bit analog-to-digital converters (MOTU HD 192). The narrowband
optical filters (CVI) have an 830 +/- 10 nm center wavelength and an out-of-band
rejection of OD4, thus blocking the excitation light while passing the fluorescent and
reference signals. An aspheric lens is used to collimate the light to optimize the blocking
of excitation light by the narrowband interference filter and enhance fluorescent signal
detection. With this scheme, we acquire frequency-encoded fluorescence emission and
reference transmission (used to normalize the measured fluorescence) light levels
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concurrently at each detector. This ratio-metric data allows DOT reconstructions using
the normalized Born approximation, resulting in a map of quantified fluorochrome
distribution. All data are acquired at a frame rate of 30 Hz. A total of 108 measurements
from source-detector pairs representing the 1st, 2nd, and 3rd nearest-neighbors are used
for image reconstruction. Further design elements and capabilities of the fiber-based,
video-rate FMT are detailed in the previous chapter (Metasebya Solomon et al.).
DOT imaging fiber array: The imaging array is composed of a grid of alternating
sources (12) and detectors (13). Light from the sources is coupled into 0.5 numerical
aperture with 2.5 mm diameter fiber bundles made of borosilicate glass sheathed with
lightweight silicone. The DOT imaging array composed of flexible silicone with rightangle fibers is integrated with the NanoSPECT/CT system.

3.2.2

SPECT/CT Acquisition

To test the compatibility of inserting the fiber-based FMT into nuclear platform, we
used

a

NanoSPECT/CT

platform

(Bioscan,

Inc.,

Washington,

D.C.).

For

NanoSPECT/CT scanning, first, CT was performed (using a 45 KVP energy tube at 177
mA and 180 projections with 400 ms exposure with pitch of 1), followed by helical
SPECT of 16 projections with 60 seconds each. CT and SPECT projections were
reconstructed using InvivoScope software (Bioscan, Inc., Washington, D.C.). The highresolution NanoSPECT/CT anatomical and radioactive data-sets have isotropic voxel
size of 0.4 and 0.6 mm respectively.
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3.2.3

MOMIA Synthesis

DOTA-Gly-Ser-Gly-Lys(Cypate)-E-Ahx-NH2,LS444,

was

synthesized

and

radiolabeled with 111InCl3 (MSD-Nordion, Kanata, ON, Canada, 3.0 microcuries (µCi)) in
aqueous buffer (190µl, 0.4 M sodium acetate, pH 4.5, 30 min, 98 °C) as described
previously (Zhang and Achilefu). Labeling efficiency and radiochemical purity were
checked by HPLC (Supelcosil ABZ + PLUS, HPLC Column, 15cm X 4mm, 5µm) with a
gradient of H2O and acetonitrile containing 0.1% TFA. The radiochemical purities of
peptides used in the studies were always above 95%. The specific activity was 223.0
µCi/nmol.

3.2.4

Experimental Protocol

Animal handling and preparation was performed according to the guidelines
approved by the Washington University School of Medicine Animal Studies Committee
for humane care and use of laboratory animals. A flowchart of the acquisition timeline is
presented in Figure 3.1A. The rats (n=5, 200-250 g Female Sprague Dawley, HSD,
Indianapolis, IN) were first anesthetized via a mixture of ketamine and xylazine (85
mg/kg and 15 mg/kg IP). The MOMIA imaging agent (100 µL of 111In-LS444) was
then administered via forepaw injection. Concurrent FMT/SPECT/CT imaging was
performed immediately after injection.
The DOT imaging fiber array was securely positioned on top of the rat, which was
then advanced into the NanoSPECT/CT imaging chamber (Figure 3.1B). The
SPECT/CT scanning regions were selected to include the injection site as well as the
DOT imaging pad by top-view topogram. CT was performed followed by helical
SPECT, with total acquisition times of 5 and 16 minutes respectively. To evaluate the
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influence of the DOT array on the SPECT/CT data-sets, we also acquired SPECT/CT
data without the DOT fiber array with the same imaging protocol as described earlier
(Figure 3.1C).
For reference and verification of

111

In-LS444 uptake by the lymph nodes (LNs),

reflectance fluorescence images were acquired in vivo before and after removal of
overlying skin following euthanasia using the near-infrared (NIR) reflectance
fluorescence system (Pearl, LiCor Biosciences, Lincoln, NE). Lymph nodes were excised
post-mortem and examined with the Pearl imaging system and dosimeter to further
validate the origin of the fluorescent and the radioactivity signals respectively. In
addition, the resected lymph nodes were frozen in OCT and sectioned in the cryostat to
8-µm thickness. NIR fluorescence (775 +/- 55 nm excitation and 810 nm long pass
emission filters) and brightfield microscopy images were acquired using Olympus BX51
upright epifluorescence microscope (Olympus America, Center Valley, PA). The same
slides were stained with hematoxylin and eosin (H&E) and imaged with fluorescence
microscopy.
To evaluate the performance of the system as a function of depth, we followed the
approach used for the stand-alone FMT system (chapter 2) (Metasebya Solomon et al.),
but in this instance with MOMIA targets. The tissue mimicking phantoms were
constructed by mixing agarose (Sigma-Aldrich, Saint Louis, Missouri) with intralipid
(20% fat emulsion, Fresenius Kabi, Germany), and India ink (Speedball, Statesville,
North Carolina) to obtain the appropriate absorption and scattering properties with µa =
0.19 cm-1 and µ's = 3.4 cm-1. The mixture was poured into a mold and allowed to
solidify at room temperature. Targets consisting of 3 mm diameter plastic tubes filled
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with the MOMIA agent were prepared and embedded at 4, 7, 10 mm depths in the tissue
simulating phantoms. The imaging protocols described above were implemented to
acquire optical and nuclear data-sets of the phantoms with targets at different depths.
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Figure 3. 1: Schematic experimental setup and timeline of the multimodal experimental
protocol. (A). Timeline of the multimodal experimental protocol. (B) Picture showing
the placement of the fiber array on a preclinical animal model before advancing into the
NanoSPECT/CT imaging chamber. (C) Schematic of the fiber array to demonstrate its
effect on the transmitted x-ray beam.
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3.2.5

Fluorescence DOT Reconstruction

We generated a subject-specific three-dimensional (3D) finite-element model (FEM)
(Figure 3.2). Using anatomical data of rats obtained from 3D X-ray CT projections
(Figure 3.2A), we created a tetrahedral mesh using MimicsTM with a maximum internodal distance of 1 mm both on the surface and within the mesh volume. The mesh,
composed of 400,399 linear tetrahedral elements connected by 67931 nodes, was
segmented into two tissue types: bone and soft tissues and assigned their corresponding
optical properties (µa = 0.17 cm-1, µ's = 24 cm-1 and µa = 0.19 cm-1, µ's = 34 cm-1
respectively) (Figures 3.1C and D). A heterogeneous tissue model was employed because
previous studies have shown improvements relative to light models that assume
homogeneous optical properties (Metasebya Solomon et al.; Niedre, Turner and
Ntziachristos; Dehaes et al.; Heiskala et al.; Eggebrecht et al.). For the tissue-simulating
phantom imaging, we also used the 3D phantom X-ray CT projections and created a
homogeneous mesh and assigned the corresponding optical properties (µa = 0.19 cm-1,
µs' = 34 cm-1). A second anatomical CT data-set of each rat and tissue mimicking
phantom was obtained with DOT fibers in place and was used to obtain the 3D
coordinates of the optodes (sources and detectors) positions (Figure 3.1B). The resulting
FEM mesh and co-registered source and detector locations were used for light modeling
(Figure 3.1E).
The light transport through the tissue was calculated using NIRFAST following our
previously reported methods (Dehghani et al.). Briefly, an adjoint approach to
constructing the Jacobian was used to construct a sensitivity matrix. The construction of
the sensitivity matrix specific to fluorescence imaging follows the methods previously
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described (see chapter 2 (Metasebya Solomon et al.)). The sensitivity matrix maps the
relationship between the optical parameters (fluorescence distribution) and the
measurements (Ntziachristos and Weissleder "Experimental Three-Dimensional
Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born
Approximation") following the normalized Born approach (Metasebya Solomon et al.).
We directly invert the sensitivity matrix via a Moore-Penrose generalized inverse
(Metasebya Solomon et al.; Culver, Durduran, et al.). The experimental source-detector
measurements are converted into images by matrix multiplication with the inverted
matrix. The recovered fluorescence yield of the tissue at each FEM node is then
presented in 3D. The mesh nodes are then transformed to a voxellated threedimensional space of 1 mm isotropic voxel space for integration with SPECT/CT (the
point spread function (PSF) of the FMT system is ~1.2 cm at 1 cm depth (Metasebya
Solomon et al.).
The accuracy of the reconstructed FMT image is further improved by using the
radioactivity measurement obtained from SPECT as a spatial priori to create a binary
mask. The mask is then multiplied with the simulated light propagation matrix
(sensitivity matrix) to constrain the FMT image reconstruction.

66

Figure 3.2: Fluorescence DOT Image Reconstruction. (A) An X-ray CT is used to
capture the three-dimension structure of the anatomy of a rat. (B) X-ray CT image with
the fiber array of DOT used to obtain optode positions. (C) Sagittal section of the
anatomical X-ray CT image after segmentation into bone and soft-tissue region using
MimicsTM. (D) 3D finite element model (FEM) of small animal half-body mesh
generated from CT within MimicsTM to be used for forward modeling of light
propagation.(E) Small animal mesh after projection of the optodes (source (red) and
detector (blue)). Sensitivity matrix is then generated using the mesh and the
measurement parameters as the main inputs for the FEM modeling of light in tissue
using NIRFAST (Dartmouth).
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3.2.5 Quantification of the Influence of FMT Fibers on
SPECT and CT
We evaluated the potential for the presence of the optical fibers to negatively impact
the imaging performance of the SPECT/CT imaging systems. The influence of the
optical fibers on the transmitted x-ray depends on the linear attenuation coefficient (µ)
of glass fibers at a given energy window and the thickness of the fiber arrays (l) (Figure
3.1C). The fraction of the transmitted x-ray beam is calculated using the following
− µ ⋅l
equation, I = I 0 e , where Io and I are the incident and the transmitted X-ray beams

respectively and l is the effective thickness of the glass fiber elements.
In addition, the normalized root mean square error (NRMSE) is used to quantify
the distortions induced in the nuclear data due to the presence of the optical fibers:
( X − X ref ) 2
NRMSE =

N
max( X ref )

; where X is the nuclear image with DOT fiber array and Xref

is the reference image without the optical fibers. N is the total number of image pixels.
NRMSE is computed for both the SPECT and X-ray CT data-sets.

3.2.6

Quantifying Image Quality: Localization Accuracy

The localization accuracy of the FMT reconstruction compared to their
corresponding SPECT data-sets was evaluated by calculating the absolute error in the
center of masses’ (of the optical and nuclear contrasts) of the lymph node volumes. The
mean fluorescence and radioactivity intensity values in the XYZ-planes were computed
for each subject from the reconstructed nuclear and optical data-sets to compute the
center of masses (COMs). In addition, the absolute error of the COMs was computed to
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assess the positional error between the fluorescence and radioactive distributions. The
COMs and COMs error of the reconstructed MOMIA tubes were also computed by
averaging the fluorescence and radioactive intensity values for each experimental depth.
In addition, quantitative comparison of the difference in spatial resolution was quantified
by comparing the volumetric ratio of the ROIs between the nuclear and optical data-sets
of the various depths of the reconstructed tubes.

3.3

Result
The goal of this study was to demonstrate the feasibility of combining fiber-based

FMT with NanoSPECT/CT. This combined nuclear-optical platform obtained data
from both contrast mechanisms concurrently in space and time. Signal from a
monomolecular multimodal imaging agent (MOMIA), 111In-LS444, was used to facilitate
the spatial integration of the nuclear and optical data.
The potential influence of the optical fibers on the nuclear imaging data-sets was
evaluated both by computing the X-ray beam attenuation due to glass fibers and, more
directly, by measuring the variance introduced into the CT and SPECT signals by the
DOT fiber array. The experimentally derived transmission losses for the X-ray beam
were consistent with the trends of the theoretical estimates based on attenuation
coefficients (energy dependent) of the glass fiber (Table 3.1). Model calculations estimate
the X-ray beam transmission through the fiber array to be 31% for CT (45 keV) and 68
% for SPECT (245 keV).
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SPECT

CT

Radiation Energy (E)

245 keV (111In)

45 keV

Attenuation coefficient of glass, µ(E), cm-1

0.256

0.781

Thickness (l ) in cm

1.5

1.5

Transmission [%]

68

31

Table 3. 1: Evaluation the effect of fluorescence DOT fiber arrays on the transmitted
X-ray beams of the nuclear imaging system
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Figure 3. 3: Evaluating the influence of fiber arrays on SPECT and CT images: (A) Xray CT image of a rat with the fiber array of DOT. (B) X-ray CT image of the same rat
shown after removing the voxels related to the fiber array of the DOT. (C) X-ray CT
acquired after removing the DOT imaging pad. The anatomical structures acquired
without the fibers are used to display the fluorescence and radioactive distribution for all
5 rats. (D) SPECT data acquired at the presence of DOT fiber array depth in a rat
following injection of multimodal imaging agent,111In-BS255, into the left forearm. (E)
SPECT data of the same rat acquired after removing the fibers.
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The computation of the NRMSE also demonstrated the existence of distortion
introduced by the optical fibers (Figure 3.3A) in the nuclear data. The NRMSE between
the X-ray CT anatomical data with and without FMT imaging fibers (Figure 3.3B and
3.3C) is 8.5%. The NRMSE between the radioactive data-sets acquired in the presence
(Figure 3.3D), and absence (Figure 3.3E) is found to be 3.1 +/- 1.3 %, which also
accounts for the additional MOMIA accumulated in LNs during the process of acquiring
the reference SPECT measurements. For improved visual reference, the fluorescence
and radioactive data are co-registered and displayed on anatomical x-ray CT obtained
after removing the DOT fiber arrays (Figure 3.3E) for the remainder of the manuscript.
Images of the MOMIA targets in tissue mimicking phantoms confirm the
localization of the targets in the range of the depths from 5-10 mm (Figure 3.4, Tables
3.2 and 3.3). The average absolute error between the COM of the optical and nuclear
data-sets for all three depths was 4.1 +/- 2.1 mm. The average depth dependent spread
of the volume of the FMT compared to the SPECT was 2.4 +/- 0.95 after thresholding
at 30% maximum.
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Figure 3. 4: Depth sensitivity analysis with phantom studies. (A) 3D finite element
model (FEM) mesh of the tissue phantom with the positions of the optodes (source
(red) and detector (blue)). These were used to model light propagation. (B) Sagittal and
Transverse Views of reconstructed experimental data from a 3mm tube target, filled with
MOMIA contrast, whose center of mass is located at either 4, 7 or 10 mm depths. The
fluorescence data shown is thresholded to >30% of max sensitivity. (C) Sagittal and
transverse view of reconstructed fluorescence tube after incorporating SPECT contrast
as a prior in the reconstruction. (D) Sagittal and transverse view of the SPECT-CT
image demonstrate localization of the MOMIA at various depths.
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COM {X, Y, Z}
in mm

COM
Error
(mm)

DOT to SPECT
Volumetric
Ratio

DOT to SPECT
Volumetric Ratio
(>30 % maximum
fluorescence
intensity)

3.4

3.7/1

1.3 /1

6.4

4.3/1

2.9/1

2.5

5/1

3/1

DOT = {8.4, 4.6, 31.9}
Shallow

SPECT =
{11.7,4.7,31.5}
DOT = {12.6,6.7,31.9}

Mid

SPECT =
{10.1,7.4,37.7}
DOT = {12.3,7.6,41.2}

Deep

SPECT =
{11.2,9,39.5}

Table 3. 2: Quantitative comparison of the localization between nuclear and optical data
sets.

COM {X, Y, Z} in mm
Shallow

DOT = {10.9, 4.1, 34.1}
SPECT = {11.7,4.7,31.5}

COM Error
(mm)

DOT to SPECT Volumetric
Ratio

2.6

0.9/1

2.9

0.85/1

2.3

0.7/1

DOT = {9.6,6.3,35.1}
Mid

Deep

SPECT = {10.1,7.4,37.7}
DOT = {11.1,7.4,37.7}
SPECT = {11.2,9,39.5}

Table 3. 3: Quantitative comparison of the localization between nuclear and optical data
sets when SPECT is used to constrain the DOT reconstruction.
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The co-registered molecular information with its corresponding anatomical
structure, Figure 3.5, demonstrates the feasibility of obtaining measurements with FMT
and SPECT molecular contrasts and structural information with X-ray CT. An
anatomical X-ray CT of a rat provided structural information that facilitated
segmentation of different tissue types including bone and soft-tissue. The tissue
segmented structure was used to generate a finite element mesh and the corresponding
optical properties of the different tissue types were assigned to each FEM element to
provide an accurate light propagation model for the FMT forward calculation (Figure
3.2).
Reconstructed FMT images show uptake of the MOMIA by the LNs in the axillary
region (Figure 3.5A). The localized radioactive signal in the axillary region of the
SPECT/CT image also demonstrated the uptake of the MOMIA by the axillary LNs
(Figure 3.5B). The high radioactive signals on the left forepaw, at the injection site, show
the starting point of the lymph tract that leads to the axillary nodes. Due to the limited
field of view of the FMT fiber array, the injection site is not visible in the reconstructed
FMT image.
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Figure 3.5: Representative Sentinel Lymph Node Mapping using Optical and Nuclear
Imaging Systems. (A) DOT-CT image of the fluorescent LNs shown at 2mm depth in a
rat following injection of multimodal imaging agent, 111In-LS444, into the left forearm.
(B) SPECT-CT image demonstrating localization of axillary lymph node identified by
accumulation of the multimodal imaging agent.
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The uptake of 111In-LS444 by the axillary LNs was further validated by combining
the SPECT and FMT data-sets. The co-registered FMT/SPECT/CT images, Figure
3.6A, demonstrate co-localization of the multimodal agent in a spatially coincident
region. The co-localization confirms that the radioactive and fluorescent signals originate
from the same location corresponding to the LNs. The low overlap percentage can be
attributed to the difference in resolution (or point spread function) between the optical
and nuclear imaging systems and the presence of fractional component of nonradiolabeled LS444. However, the free LS444 fractional component is expected to be
very minimal due to the high radiochemical purities of peptides used.
Having demonstrated the co-localization of the fluorescence and radioactive
distribution, we explored a simple method to incorporate the high resolution
NanoSPECT/CT radioactive data into the DOT image reconstruction to improve the
localization accuracy of the axillary LNs signal. A binary mask, created from the
radioactivity distribution of the SPECT data was multiplied with the simulated light
propagation matrix to constrain the FMT image reconstruction. The SPECT/CT
measurements fused with the FMT data-sets reconstructed with a priori, Figure 3.6B,
demonstrated an improvement in congruency of the radioactive and fluorescence signal
in the axillary regions. As a result of using SPECT as a hard prior, the overlap between
DOT and SPECT is inherently unity. Likewise, it is assumed that the fluorescent signal
originates from conjugated complexes and not from free optically active fragments. A
soft prior approach to relax these conditions is suggested below. The average spatial
discrepancy between the COM of the optical and nuclear data-sets for all five rats was
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2.68 +/- 1.0 mm and 1.33 +/- 0.85 mm before and after incorporating SPECT as a
priori respectively.

Figure 3. 6:Multimodal Sentinel Lymph Node Imaging. (A) Co-registered FMTSPECT-CT image demonstrate co-localization of the MOMIA in spatially coincident
region in 5 rats. (B) Demonstrate robust co-localization on the co-registered FMTSPECT-CT image after using SPECT as a prior.
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Reflectance fluorescence images were captured using the Pearl NIR fluorescence
imaging system before sacrificing the animal to confirm the nuclear and DOT results.
Reflectance fluorescence images acquired after euthanasia and removal of overlying skin
further confirmed MOMIA uptake by the lymph nodes localized by DOT and SPECT
(Figure 3.7A). The uptake of the MOMIA by axillary lymph nodes (inset on Figure 3.7A)
was further confirmed with combined fluorescence and bright field microscopy (Figure
3.7B). In addition, the H&E stains validate the excised organ as lymph nodes due to the
presence of centroblasts (dark zone) and centrocytes (light zone).

Figure 3.7: (A) Representative planar reflectance image of the sentinel lymph node
regions demonstrating fluorescence from the injection site (paws) and the lymph vessels
leading to the axillary lymph nodes (arrow) of the rats after euthanasia and removal of
the skin. In set fluorescence from ex vivo imaging shows MOMIA uptake in the lymph
nodes. (B) Representative microscopy images of fluorescent sentinel lymph nodes.
Montages are a composite of brightfield and fluorescence microscope at top left and
brightfield at top right. The bottom left and right represent fluorescence and H&E
stained section respectively.
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The radioactivity measured from excised LNs with a dosimeter demonstrate an
uptake of approximately 0.45+/-0.17 % µCi (n=4) of the injected dose per SLN. The
tracer uptake of sentinel nodes is highly variable as the lymph flow depends on factors
such as massaging the injection site. For instance, in a study of melanoma cancer
patients, uptake in the SLNs ranged from 0.00139-6.8% of the injected tracer dosage
(Kapteijn et al.).

3.4

Discussion
The multimodal optical-nuclear platform shown has the potential to elucidate

underlying biological mechanisms relevant to a wide array of diseases. We established the
feasibility of integrating a fiber-based, video-rate FMT system with a preclinical
NanoSPECT/CT platform. We used our recently developed MOMIA, which has the
unique structural feature that both signals (fluorescence and radioactivity) emanate from
the same source. The NIR fluorescent molecular probe, LS444, served as a contrast
agent for FMT, while the

111

ln served as a source of signal for SPECT imaging to

facilitate the fusion of the optical and nuclear data-sets with high spatial precision.
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In this chapter, we evaluated the FMT/SPECT/CT system for imaging LNs in rats.
CT provided high-resolution, co-registered anatomy. The combined optical-nuclear
imaging demonstrated co-localization of a MOMIA in a spatially coincident region. We
further demonstrated the congruency of the co-localization by incorporating SPECT as a
prior in the DOT reconstruction. The average spatial discrepancy in the COMs of the
contrasts between SPECT and FMT improved from 2.68 +/- 1.0 mm to 1.33 +/- 0.85
mm after incorporating SPECT into the FMT reconstruction.
Data-sets acquired separately with optical and nuclear platforms have been
integrated previously (Kapteijn et al.; Nahrendorf et al.). For instance, Nahrendurfet et.
al. demonstrated the similarity between FMT and PET by combining the two data-sets
acquired sequentially on two different scanners using fiducial markers to co-register the
data (C. Q. Li et al.). A strength of the current simultaneous optical-nuclear system is
that it avoids potential misalignment of data-sets due to involuntary non-uniform
movement of tissues during repositioning. Furthermore, the datasets in the presented
study are co-registered in time. The first small animal study where optical imaging (scan
rate not reported) was physically integrated into a PET system was reported by Li et al.
(Nahrendorf et al.). Localization of the tumor with simultaneously acquired nuclear and
optical datasets was performed after injection of two separate contrast agents (for
fluorescent and radioactive detections) at different time points, separated by 24 hours,
thus the data-sets were not co-registered in time. Further, acquisition of the anatomical
information using a different scanner might lead to co-registration error of the functional
molecular data with reference anatomy. To a significant extent, the system presented in
this paper addresses many of these difficulties by combining three modalities
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(FMT/SPECT/CT) within a single device. The FMT/SPECT/CT platform acquires the
different functional (fluorescent and radioactive) and anatomical data either
simultaneously or sequentially without moving the subject from the bed. This design
essentially eliminates differences in subject positioning and minimizes misalignment due
to involuntary internal organ motion.
While the current study does not focus on the dynamics of the lymph node
accumulation, we have previously reported the capability of the FMT system for
dynamic imaging by monitoring and generating time-course data of the lymphatic
dynamics for indocyanine green (ICG) (Metasebya Solomon et al.). Accumulated dye in
the axillary region of rats was imaged to a depth of 10-12 mm over a 10-minute timecourse. Future studies will be needed to explore dynamic imaging of pharmacokinetics
and pharmacodynamics for multimodal contrast agents.
Optical imaging can leverage the SPECT and CT information to improve accuracy
during data processing and image reconstruction (Cao and Peter; A. Li et al.). For
instance, we generated a small animal 3D finite-element model (FEM) using the 3D
anatomical projections obtained from an X-ray CT to improve forward modeling of light
propagation. In addition, incorporating SPECT data into the FMT reconstruction
augmented the localization accuracy. An important future area of work is in developing
algorithms to incorporate the SPECT data as a soft-prior in the FMT reconstruction to
optimize the fusion of the two data types (Cao and Peter).
The current FMT system setup has high dynamic range and linear response and
accurate localization at various depths as shown with phantom studies. However, several
potential improvements of the fiber-based, video-rate FMT system can still be identified.
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For instance, the sensitivity of the optical imaging in general is expected to decline with
imaging depth, while SPECT has no depth limitation and easily extends to whole-body
imaging. Possible extensions on the current design include extending the FMT field of
view for more complete coverage. The DOT imaging array shape and size can be
designed based on application. For example, the imaging array could have a cylindrical
shape with extended sources and detectors for whole-body imaging. The potential for an
expanded fiber array system with up to 48 sources and 48 detectors has been
demonstrated for brain imaging in humans (White et al.). A higher-density imaging array
could also potentially increase the resolution, particularly at the shallower depths for
accurate localization of the target (Culver, Ntziachristos, et al.). A second limitation is
the existence of distortion/artifacts on the x-ray CT images due to the high attenuation
coefficient of borosilicate glass fibers compared to the bone. The possibility of whether
switching to optical fibers composed of materials with lower attenuation than bone
would reduce the artifacts remains a question for future investigation.
Another area of future work is to leverage the complementary contrast mechanisms
of SPECT/FMT to evaluate biological mechanisms. MOMIAs that use activatable
optical contrast mechanisms provide complementary information to the "always-on"
SPECT information. SPECT can be used for whole-body imaging to localize the
diseased tissue based on maps of the concentration of molecular targeted imaging agents
while the FMT would report local molecular events, such as enzymatic activity, to
monitor therapeutic response (H. Lee et al.).

83

3.5

Conclusion
We demonstrated integration of a fiber-based, video-rate fluorescence mediated

tomography system with a preclinical NanoSPECT/CT platform. The video-rate FMT
can accommodate the various imaging bore sizes of nuclear imaging systems due to the
flexibility of the imaging fiber array. We used a monomolecular multimodal imaging
agent such that the nuclear and optical signals emanated from the same regions to
facilitate the fusion of both data-sets with high spatial precision. The depth profiling
capability of the FMT was confirmed in phantoms by localizing MOMIA targets in
tissue mimicking phantoms in the range of depths from 5-10 mm. The average absolute
error between the COM of the optical and nuclear datasets for all three depths was 4.1
+/- 2.1 mm and the depth dependent spread of the volume of the FMT compared to
the SPECT was 2.4 +/- 0.95 after thresholding at 30% maximum. For in vivo imaging,
we used the anatomical X-ray CT data-sets to generate 3D finite-element model for light
propagation. Co-localization of the MOMIA in both the FMT and SPECT contrasts was
demonstrated. We also observed improvement in spatial correlation of the co-registered
datasets after incorporating SPECT as a priori to constrain the FMT data reconstruction.
The average spatial discrepancy of the LNs COMs between FMT and SPECT improved
from 2.68 +/- 1.0 mm to 1.33 +/- 0.85 mm after incorporating the SPECT as a prior
into the FMT reconstructions. These results suggest that integrated multimodal
FMT/SPECT/CT has the potential to become a powerful and practical tool for a broad
array of real time imaging applications.
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Chapter 4
FMT/CT Guided Dynamic Imaging of
Optical Tracers for Small Animal
Imaging
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4.1

Introduction
Dynamic fluorescence imaging is an emerging technology that can provide

enhanced non-invasive functional and molecular level details and is a promising tool for
detection of abnormal anatomical or physiological conditions based on kinetic
parameters related to perfusion, pharmacokinetics, and tissue metabolism.
Currently, dynamic fluorescence imaging has been applied to studies of
biodistribution of various optical agents in basic biological research (Achilefu and
Dorshow; Amoozegar et al.; El-Desoky et al.; Goiffon et al.; Hillman et al.; Hillman and
Moore; Patwardhan and Culver; Welsher, Sherlock and Dai). While dynamic imaging via
fluorescence reflectance imaging (FRI) recently allowed segmentation of various internal
organs based on their different kinetic behaviors(Hillman and Moore; Welsher, Sherlock
and Dai), FRI sensitivity declines quickly with depth and a 2D geometry precludes coregistration with 3D modalities such as MRI, CT, PET or SPECT. Three-dimensional
fluorescence mediated tomography (FMT) provides improved deep tissue sensitivity,
volumetric localization and increased quantitative accuracy. FMT systems typically image
on time scales of minutes to hours, which is too slow to monitor the uptake dynamics of
a vascular injection.
In this work, we overcome this limitation and demonstrate dynamic tomography of
fluorescent diagnostic imaging agents in healthy mice and in mice with liver disease. We
demonstrate that video-rate FMT is fast enough to enable imaging of cardiac, respiratory
and pharmacokinetic induced dynamic fluorescent signals and that the real-time uptake
of injected agents can be deduced from these measurements. Fiber-based, video-rate
FMT can additionally improve the flexibility of imaging by adapting to varying tissue
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curvatures and performing simultaneous multiple point illumination and collection, thus
increasing the imaging frame rate. In addition, for improved delineation of target tissues,
we have combined FMT with CT to obtain complementary information. X-ray CT
provides anatomical information while FMT provides dynamic functional information.
Anatomically guided dynamic fluorescence mediated tomography was made possible by
combining our recently published fiber-based, video-rate FMT system (Metasebya
Solomon et al.) with preclinical NanoSPECT/CT (Bioscan).
Dynamic fluorescence mediated tomography (DyFMT) used in conjunction with
tracer kinetic modeling promises to be an effective tool for non-invasive quantification
of molecular imaging analysis (Liu et al.; Milstein, Webb and Bouman). Tracer kinetic
modeling allows extraction of clinically or experimentally relevant information related to
physiological and molecular processes. Kinetic models require two main measurements
of tracer concentration over time as inputs (van den Hoff; Willemsen and van den Hoff).
The two key measurements are tracer time course in arterial blood, used as a forcing
function, and the corresponding tracer time course in the organ of interest, the
“response.”
Some challenges exist that limit the application of compartment modeling on a
routine basis or for longitudinal studies relating to small animal imaging (Laforest et al.;
van den Hoff; Willemsen and van den Hoff). The gold standard for obtaining an input
function is through manual acquisition of arterial blood samples, a technique that yields a
limited temporal resolution (Laforest et al.). In addition, frequent arterial blood sampling
is an invasive technique that has multiple drawbacks. First, the number of arterial blood
samples collected is limited because it is inconvenient and hard to access the small blood
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vessels of small animals. Second, the amount of blood volume withdrawn is limited to a
small fraction of the total blood volume of the animal to avoid blood depletion and keep
the animal alive. Furthermore, the loss of blood may perturb the animal physiology and
induce a bias in the experimental outcome. It may also limit or prevent repeated
assessment of the same animal for longitudinal studies. Non-invasive techniques such as
factor analysis methods and region-of-interest based (image-derived) input functions are
proposed to resolve some of the challenges associated with serial arterial blood sampling
for routine implementation of kinetic modeling in small animal studies (Laforest et al.;
van den Hoff; van der Weerdt et al.; Willemsen and van den Hoff; Wu, Hoh, et al.; Wu,
Huang, et al.; Hoekstra, Hoekstra and Lammertsma).
In this work, we propose to implement our application using a plasma input
function, derived from dynamic FMT images. This approach is noninvasive in nature
and helps simplify the scanning protocol. We demonstrate, for the first time, the
feasibility of implementing time traces extracted from highly vascularized region-ofinterest, the heart region, as image-derived input function (IDIF) for dynamic
fluorescence tomography. The IDIF was validated against the reference input functions,
arterial blood samples, to fulfill the requirement of compartmental modeling and kinetic
parameter estimation for fluorescence dynamic imaging studies. The second input to the
compartmental modeling, time resolved signal curves of target regions, was obtained
from the fluorescence dynamic imaging series guided by organ locations shown in the
corresponding X-ray CT data. Furthermore, feasibility studies were performed to
distinguish healthy and diseased target regions uptake and clearance rates by
implementing a two-compartment model. In summary, this technique provides a
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powerful pharmacokinetic analysis of optical agents, with the potential for detecting the
disease state of the internal organs and monitoring their response to therapeutic agents.

4.2

Materials and Method

4.2.1

Fiber-based, video-rate FMT System

For this study, we used our previously published fiber-based, video-rate
fluorescence mediated tomography system, which consists of a grid of alternating 12
sources and 13 detectors (Metasebya Solomon et al.) Each source position is composed
of two near infrared laser diodes (785 nm, Thorlabs DL7140-201S, and 830 nm,
Thorlabs HL8325G) with dedicated drivers and control lines for each source to allow
flexible software configurable source encoding (frequency- and time- encoding). Light
sources are coupled into 2.5 mm diameter fiber bundles made of borasilicate glass
sheathes with lightweight silicone. The detection channels use optically-filtered discrete
avalanche photodiodes (Hamamatsu C5460-01) digitized with dedicated 24-bit analogto-digital converters (MOTU HD 192). The custom made narrowband optical filters
(CVI) have an 830 +/- 10 nm center wavelength and an out-of-band rejection of OD4,
thus blocking the excitation light while passing the fluorescent and reference signals. An
aspheric lens is used to collimate the light and optimize the blocking of the excitation
light by the narrowband interference filter in order to enhance fluorescent signal
detection. With this scheme, we acquire frequency-encoded fluorescence emission and
reference transmission (used to normalize the measured fluorescence) light levels
concurrently at each detector. This ratio-metric data allows DOT reconstructions using
the normalized Born approximation, resulting in a map of quantified fluorochrome
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distribution

(Ntziachristos

and

Weissleder

"Experimental

Three-Dimensional

Fluorescence Reconstruction of Diffuse Media by Use of a Normalized Born
Approximation"). All data are acquired at frame rate of 30 Hz. A total of 88
measurements from source-detector pairs representing the first (6 mm) and second (13
mm) source-detector pairs are used for image reconstruction. The DOT imaging array
composed of 3 cm wide by 3 cm high flexible silicone with right-angle fibers is
integrated with the NanoSPECT/CT system.
The ratio-metric data of light intensities of transmission and fluorescent acquired
concurrently at each detector is discretized according to the normalized Born approach
to obtain y=Ax, which is followed by direct inversion using a Moore-Penrose
generalized method to obtain fluorescence image reconstruction (Culver, Siegel, et al.;
Ntziachristos

and

Weissleder

"Experimental

Three-Dimensional

Fluorescence

Reconstruction of Diffuse Media by Use of a Normalized Born Approximation";
Patwardhan and Culver; M. Solomon, B. R. White, et al.; Zeff et al.). Optical properties
at the reference wavelength of µa = 0.1 cm−1 and µ's = 10 cm−1 were used to model the
optical properties of the mouse for in vivo studies (Cheong, Prahl and Welch). Further
reconstruction and design details as well as capabilities of the fiber-based, video-rate
FMT are detailed in a previous publication (Metasebya Solomon et al.).

4.2.2

CT Acquisition

For improved delineation of tissue/target volumes, we have combined FMT with
microCT to obtain complementary information. X-ray CT provides anatomical
information while FMT provides dynamic functional information. Our fiber-based,
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video-rate FMT system was inserted into NanoSPECT/CT platform (Bioscan, Inc.
Washington, D.C.) for co-registration of fluorescence and nuclear imaging data sets. The
rat bed and 9-pinhole collimator sets were used to accommodate mouse and DOT
imaging fiber array as previously described (chapter 3). The whole body CT scanning
regions, including the DOT imaging pad, were selected by top-view topogram and the
total acquisition time was 5 minutes. CT scanning was performed using a 45 KVP energy
tube at 177 mA and 180 projections with 400 msec exposures with pitch of 1. CT
projections were reconstructed using InvivoScope software (Bioscan, Inc. Washington,
D.C.). The high-resolution NanoSPECT/CT anatomical data sets have isotropic voxel
size of 0.4 mm.

4.2.3

Experimental Protocol

Animal handling and preparation was performed according to the guidelines
approved by the Washington University School of Medicine Animal Studies Committee
for humane care and use of laboratory animals. A flowchart of the acquisition timeline is
presented in Figure 4.1. Mice (n= 5 healthy and n=6 mice with liver disease) were
anesthetized with an intraperitoneal injection of ketamine (85 mg/kg) and xylazine (15
mg/kg) cocktail.
The dynamic fluorescence intensity was monitored for 10 minutes following tail
vein bolus injection of 80 𝜇M of ICG (Indocyanine green, Sigma-Aldrich, St Louis, MO)
via a catheter secured in the tail vein. The DOT imaging fiber array was securely
positioned on the ventral side of each mouse to image the heart, lung and liver regions
(Figure 4.1B). We continuously acquired images at the rate of 30 frames per second (fps)
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to capture the initial rapid change in signal levels associated with the uptake and washout
of the optical tracer in the blood and different tissues, with maximum time resolution.
Arterial blood samples were collected before and during the optical data acquisition
period using micropipette tubes by capillary action. Initially, continuous blood sampling
from the tail artery is achieved every 15 seconds for the first two minutes in order to
capture the fast dynamics of the first few minutes of the contrast agent time course. The
continuous sampling was performed every 1-minute until the end of the imaging session
to minimize the effect of blood loss on the animal physiology. The micropipette tubes
are then imaged using the Pearl near-infrared (NIR) fluorescence imaging system (LiCor
Biosciences, Lincoln, NE).
To induce liver apoptosis, FasL (Jo2 clone, BD Pharmingen) was administered
intraperitoneally into the mice (n=6) (0.15 ug/g) 4 hours before imaging (Ogasawara et
al.; Janin et al.). FasL is a monoclonal antibody that targets ligand Fas receptors (also
known as “Death” receptors) and activates apoptotic responses of hepatocytes and
endothelial cells that express the Fas receptors (Ogasawara et al.; Janin et al.; Goetz et
al.). At the end of the dynamic fluorescence data acquisition period, we also acquired
anatomical X-ray CT data with and without the DOT fiber array using imaging protocol
as described earlier without moving the animal.
For reference and verification of ex vivo ICG uptake by different organs, superficial
fluorescence images of the excised organs were acquired at the end of imaging
experiments after humane euthanasia using the Pearl near-infrared (NIR) reflectance
fluorescence system. Healthy and diseased livers were isolated and fixed in 10 %
formalin for hematoxylin and eosin (H&E) staining and histological analysis.
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4.2.4

Segmentation

Using anatomical data of the mouse obtained from 3D X-ray CT projections
(Figure 4.1C), we created a binary mask for each target regions (heart, lung and liver).
The XYZ-coordinates of the mask are manually selected from the corresponding
anatomical locations. A second anatomical X-ray image of mouse obtained with DOT
fibers is used to obtain source-detector positions (Figure 4.1B). An affine transformation
is performed to transform the masks XYZ-coordinates into a DOT space for
multiplication with the reconstructed fluorescence dynamic data to extract its
corresponding time courses by averaging the voxels fluorescence intensity. The accurate
segmentation of the different functional regions is key since the average voxel time trace
is dependent on it. Any change of the time trace, for example delay in time, might lead to
an error in kinetic parameters estimation. To address this issue, we selected the masks
coordinates well within the target regions.
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Figure 4.1: Dynamic Fluorescence and Anatomical Data Acquisition Protocol. (A)
Schematic showing the placement of the fiber array on ventral side of a mouse to
demonstrate the source-detector arrangement and the imaging field-of-view. (B) X-ray
CT image with the fiber array of DOT used to obtain source-detector positions for
anatomical co-registration of the dynamic FMT data. (C) An X-ray CT is used to capture
the three-dimension structure of the anatomy of a mouse for segmentation of target
regions. (D) Timeline of the fluorescence and anatomical data acquisition protocol.
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4.2.5

Compartment Modeling

First, the feasibility of implementing a region-of-interest based forcing function was
validated against the reference arterial blood samples. Serial arterial blood samples were
collected as the gold standard for pharmacokinetic analysis for validation of dynamic
fluorescence imaging. Image-derived input functions (IDIF) were constructed from
heart region time traces. Temporal correlations were determined using Pearson
correlation of the heart region time traces with corresponding reference arterial blood
samples, thus producing correlation r-value for each mouse. Second, the IDIF was used
as input for a two-compartment model to estimate and assess ICG pharmacokinetics in
healthy mice and mice with liver disease extracted time traces from lung and liver
regions. To assess the in vivo pharmacokinetics of ICG in the liver and lung with and
without drug treatment, a widely used two-compartment trapping model with three
parameters was employed (Figure 4.2)(Willemsen and van den Hoff; van den Hoff).
The ''vasculature" compartment represents the kinetics of ICG remaining in
systemic circulation. The clearance of ICG from the systemic circulation is attributed to
its trapping and excretion exclusively into the bile through the liver without undergoing
any biotransformation. In this model, the ''tissue" compartment is split into twocompartments – EES and Internalized. We postulate that free ICG in the blood can
reversibly extravasate into the tissue while no extravasation from albumin bound ICG to
tissue is expected except in the liver (Berezin, Guo, Akers, et al.). Therefore, the
"Extracellular Extravascular Space" compartment represents the time-resolved reversible
extravasation of ICG in different organs of interest (lung and liver). The forward and
reverse rate-constants of ICG between the blood and tissue are denoted by k1 (sec-1) and
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k2 (sec-1), respectively. The ''Internalized" compartment represents the concentration of
ICG that remained trapped in the tissue during the data acquisition period. The tracer is
trapped into the tissue at a rate constant of k3 (sec-1).
The tissue compartment, CT, is represented as the solution to a linear differential
equation (Eq 1) derived assuming that rates of transport are given by a rate constant
multiplied by the concentration of the different compartments of our model (Berezin,
Guo, Akers, et al.; Willemsen and van den Hoff; van den Hoff). The solution of the
differential equation is convolved with the image-derived forcing function, Cbl (Eq2)
(Willemsen and van den Hoff; van den Hoff). Next, the output of the convolution is
used as an input and the Nelder-Mead Simplex algorithm is used to optimize the kinetic
parameters k1 through k3 against the target regions dynamic FMT data.

This is

implemented through the fminsearch function in Matlab (MatLab 7.14, The MathWorks,
Inc. Natick, MA). The overall uptake rate constant of ICG (K) (Eq 3) in the liver and
lung is computed to compare their difference in overall ICG uptake rate (Willemsen and
van den Hoff; van den Hoff). The accuracy of the fitted ICG curves were compared and
validated against their matching dynamic FMT data using Pearson correlation.
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Figure 4.2: Two-compartment model implemented to estimate ICG kinetic rate
constants (k1, k2 and k3 (sec-1)) of the lung and liver tissues in healthy mice and mice
with liver disease.

4.3

Results
The goal of this study was to demonstrate the feasibility of implementing video-rate,

fiber-based FMT-CT as a fast and non-invasive tool to obtain IDIF and assess organ
function based on the quantitative output of kinetic modeling. The different processing
steps involved in obtaining image-derived input functions and kinetic modeling steps to
estimate rate constants of regions-of-interest are outlined in Figure 4.3.
Fluorescence concentrations over time were obtained from the dynamic imaging
series for target regions (heart, lung and liver) guided by their corresponding anatomical
x-ray CT data (Figure 4.4 and Figure 4.5). Figure 4.4 illustrates typical subject-specific
masks definition of regions-of-interest manually generated from anatomical X-ray CT
projections. The masks are used to constrain reconstructed FMT data and obtain ICG
dynamics for anatomically defined regions.
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Figure 4.3: Flow chart demonstrating steps towards quantitative fluorescence mediated
tomography (FMT). IDIF= Image-Derived Input Function, ABS= Arterial Blood
Samples.
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Figure 4.4: Illustration of typical masks definition of target regions generated from
anatomical X-ray CT data. (A) Representative coronal view of heart, lung, and liver (left
to right) regions masks combined with the corresponding X-ray CT data. (B)
Representative sagittal view to demonstrate the depth profile of the combined target
regions masks and the profile of the DOT sensitivity matrix (blue). The target regions
are within the DOT sensitivity. (C) Three-dimensional representation of the heart, lung
and liver masks co-registered with its anatomical X-ray CT data. The far right image is
the combined heart, lung and liver masks co-registered with its corresponding X-ray CT
data. The masks are used to extract their corresponding ICG time courses to estimate
the kinetic rate constants of each region of interest.
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The DOT images of ICG dynamics of heart, lung and liver regions were coregistered with its corresponding anatomical X-ray CT projections for healthy and antiFas-treated groups (Figure 4.5). Representative sagittal and coronal views of the target
regions masks are shown in Figures 4.5A and 4.5C. Coronal slices that best display the
dynamic fluorescence data from the heart, lung and liver are shown in Figure 4.5B and
4.5D. Representative time traces extracted from target organs corresponding to their
anatomical locations demonstrated distinct ICG dynamics due to their different ICG
pharmacokinetics (in healthy mouse (Figure 4.5E) and averaged over all five healthy
mice and all six mice with liver disease (Figure 4.5F)). Each organ demonstrated distinct
ICG dynamics due to their different ICG pharmacokinetics. The time traces
demonstrated ICG accumulation in the liver, which is associated with ICG uptake by
hepatocytes	
   prior to elimination in the bile. In contrast fluorescence signal from heart
and lung regions rapidly decreased during the same time period, corresponding to ICG
clearance from the blood.
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Figure 4.5: Imaging of ICG Dynamics in Mice. (A & C) Sagittal and coronal views of
the combined heart-liver masks (left to right). The blue lines of the sagittal views indicate
the position of the coronal slice used to display the dynamic FMT-CT data. (B & D)
Coronal view of the reconstructed fluorescence dynamic tomography, after
segmentation, and co-registered with its corresponding anatomical X-ray CT following
bolus injection of ICG into the tail vein of a healthy mouse. (E) Average time courses
of pixels extracted from the heart, lung and liver regions of a representative healthy
mouse shown above. Each organ demonstrates distinct ICG dynamics due to their
different ICG pharmacokinetics. (F) The dynamics of ICG of heart, lung and liver
regions averaged over 5 healthy mice and over 6 mice with experimentally induced liver
apoptosis (left to right). The time traces demonstrate ICG accumulation in the liver
while the signal decreases over time in the heart and lung regions, which is associated
with ICG clearance. In addition, the time traces of mice with liver disease show high
standard deviation, which can be associated with the subject specific response to the
FasL treatment that can indirectly induce high variation on ICG pharmacokinetics.
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The feasibility of implementing time traces derived from the heart, as forcing
function for a two compartment model was validated against the gold standard method,
arterial blood samples. Time traces of ICG in collected serial arterial blood samples
shows similar dynamics to its corresponding time traces derived from the heart region
(in a representative mouse Figure 4.6A and averaged over all fiver healthy mice and six
mice with liver disease Figure 4.6B and 4.6C respectively). Time traces of the IDIF are
highly correlated temporally with their corresponding arterial blood samples with a mean
Pearson correlation coefficient of 0.95 ± 0.024 and 0.86 ± 0.083 in healthy mice (Table
4.1) and in mice with liver disease (Table 4.2) respectively. The high correlations
demonstrate that the time courses from the heart region can be used as an image-derived
forcing function for a two-compartment model to estimate ICG kinetic parameters of
the target regions, the lung and liver.

Figure 4.6: Validation of Image-Derived Input Function (IDIF) with Interpolated Serial
Arterial Blood Samples. (A) Time traces of ICG in collected serial arterial blood samples
compared to its corresponding time courses from heart region of a representative
healthy mouse. (B & C) Mean time courses of ICG dynamics in systemic circulation and
time courses extracted from heart regions and averaged of 5 healthy mice and 6 mice
with liver disease. The heart region are highly correlated with the arterial blood samples
with Pearson correlation coefficient of r=0.95 +/- 0.024 and 0.86 +/- 0.083 in healthy
mice and mice with liver disease respectively.
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Moreover, we demonstrated the feasibility of evaluating organs function by
comparing ICG kinetic parameters in regions-of-interest in mice with induced hepatic
apoptosis and healthy mice. Target regions (lung and liver) measurements and their
corresponding IDIF were used as inputs for the proposed two-compartment model. The
estimated ICG kinetic rate constants of liver and lung regions demonstrate the feasibility
of distinguishing different organs as well as healthy vs. diseased organs. Using the twocompartment model, each fitted ICG concentration curve shows high temporal
correlation with the corresponding lung and liver ICG time courses data (r= 0.95 ±
0.059 and 0.95 ± 0.028 for lung and liver regions respectively) in healthy mice (Figures
4.7A and 4.7B and Table 4.1). There is also high correlation between each fitted ICG
concentration curve and the corresponding lung and liver time courses data (r= 0.92 ±
0.047 and 0.92 ± 0.042 for lung and liver data respectively) in mice with liver apoptosis
(see Figures 4.7C and 4.7D and Table 4.2).

103

Figure 4.7: (A & C) Examples of lung and liver regions fitted ICG time courses using
the two-compartment model and their corresponding time courses obtained from a
healthy mouse and mouse with experimentally induced liver disease respectively. (B &
D) Mean dynamics of lung and liver regions ICG time courses and their corresponding
fitted ICG time traces using the proposed two-compartment model averaged over 5
healthy mice and 6 mice with liver disease respectively. Each fitted ICG concentration
curve shows high correlation with the corresponding lung ICG time courses data with
mean Pearson correlation coefficient of, r, 0.95 +/- 0.059 and 0.92 +/- 0.047 for healthy
mice and mice with liver disease respectively. Each fitted liver ICG concentration curve
is highly correlated with the corresponding liver ICG time courses data with mean
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Pearson correlation coefficient of, r, 0.95 +/- 0.028 and 0.92+/- 0.042 for healthy mice
and mice with liver disease respectively.
The average overall uptake rates of liver and lung in healthy mice were 7.4x10-4 +/5.6x10-4 sec-1 and 4.48 x10-6 +/- 1.92x10-6 sec-1 respectively, which confirms that ICG is
trapped hundredfold time more in the liver (Figure 4.8A) and that lung lower
permeability and retention rate of ICG. The liver damage alter the kinetics of ICG
compared to healthy mice as displayed by the increase in the overall rate constant of lung
and liver in diseased mice as shown in Figure 4.8B. For example, the observed delay in
excretion rate of ICG from the systemic circulation in mice with hepatic apoptosis was
caused by the sluggish ICG uptake rate of diseased liver (Table 4.3). The mean ICG
uptake rate (k1) of liver in mice with liver disease was decreased from 0.02 ± 0.022 sec-1
to 0.013 ± 0.0094 sec-1. The mean reverse rate (k2) was also diminished in mice with liver
apoptosis to 0.074 ± 0.66 sec-1 from 0.12 ± 0.11 sec-1. The ICG internalization by
hepatocytes was elevated from 0.0055 ± 0.0024 sec-1 in healthy mice to 0.0092 ± 0.012
sec-1 in mice with liver disease. ICG is mainly cleared through the liver into the bile
without undergoing any modification.
In addition, there was also an observed increase in the uptake and clearance rate of
ICG in lung of mice with liver disease compared to healthy mice (Table 4.3). For
instance, we observed an increase in lung mean uptake rate of (k1) in mice with liver
disease from 6.8x10-4 ± 3.7x 10-4 sec-1 to 0.0161 ± 0.0094 sec-1. The mean reverse rate
(k2) had also increased from 0.29 ± 0.21 sec-1 to 0.48 ± 0.39 sec-1 in mice with liver
disease. The ICG retention rate in lung cells was elevated from 0.0019 ± 0.0011 sec-1 to
0.0031 ± 0.0036 sec-1 in mice with liver disease. Moreover, the average overall ICG
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uptake rate of liver and lung increased from 7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6 to
1.03x10-3 sec-1, respectively. The observed increase in overall ICG rate constant of lung
and liver (Figure 4.8B) is associated with leaky vasculature and cell membranes due to
the experimentally induced endothelial cell apoptosis and vascular lesions after FasL
administration (Ogasawara et al.; Janin et al.).

Figure 4. 8: Overall ICG uptake rate constant of lung and liver regions. (A) Comparison
of the overall uptake rates of liver and lung regions in healthy mice. The mean overall
uptake rates of liver and lung are 7.4x10-4 +/- 5.6x10-4 sec-1 and 4.48 x10-6 +/- 1.92x10-6
sec-1 respectively, which confirms that ICG is trapped hundredfold time more in the liver
(Figure 8A) and that lung lower permeability and retention rate of ICG. (B) Comparison
of the overall uptake rates of liver and lung regions in healthy mice with anti-Fas treated
group of mice.	
  The average overall ICG uptake rate of liver and lung increased from
7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6 to 1.03x10-3 sec-1, respectively
The change in kinetic parameters is associated with the induced morphological
changes of hepatocytes (cell bodies and the nucleus) and endothelial cells that express
Fas receptors (Ogasawara et al.; Janin et al.). Liver section histology verified
morphological changes of the cell bodies and nucleus as a result of the induced
apoptosis 4 hours after administering FasL compared to healthy liver (Figure 4.9). The
extent and severity of the liver apoptosis after the FasL treatment is subject specific as
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shown in Figure 4.9B. This could be the cause of the high variation (standard deviation)
observed in the ICG time courses of mice with liver disease.

Figure 4.9: Histological analysis of liver sections of healthy mice and mice with
experimentally induced liver apoptosis. (A & B) Examples of hematoxylin and easin
(H&E) stained healthy and diseased liver sections respectively. The H&E stained liver
sections demonstrate morphological changes of the cell bodies and the nucleus as the
result of the induced liver apoptosis 4 hours after administering FasL. The extent of liver
apoptosis after the FasL treatment is subject specific as shown as an example for two
different mice in B. LD= Liver Disease.
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Healthy Mice
Pearson Correlation Coefficient (r2)
1

2

3

4

5

Mean +/- STD

IDIF vs. ABS

0.96

0.92

0.93

0.97

0.97

0.95 +/- 0.024

Liver Data vs. Fitted Curve

0.99

0.97

0.94

0.92

0.93

0.95 +/- 0.028

Lung Data vs. Fitted Curve

0.99

0.93

0.99

0.99

0.85

0.95 +/- 0.056

Table 4.1: Validation of image derived input function (IDIF) against the reference
arterial blood samples (ABS) and comparison of the two-compartment model output
with the corresponding dynamic FMT data of healthy mice.

Mice with Liver Disease
Pearson Correlation Coefficient (r2)
1

2

3

4

5

6

Mean +/STD

IDIF vs. ABS

0.94

0.76

0.76

0.95

0.85

0.87

0.86 +/- 0.083

Liver Data vs. Fitted
Curve

0.88

0.9

0.98

0.9

0.92

0.97

0.92 +/- 0.042

Lung Data vs. Fitted
Curve

0.95

0.93

0.97

0.92

0.83

0.91

0.92 +/- 0.047

Table 4.2: Validation of image derived input function (IDIF) against the reference
arterial blood samples (ABS) and comparison of the two-compartment model output
with the corresponding dynamic FMT data mice with experimentally induced liver
apoptosis.
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Healthy Mice
Mean +/- STD

Mice with Liver Disease
Mean +/- STD

k1 (sec-1)

k2 (sec-1)

k3 (sec-1)

k1 (sec-1)

k2 (sec-1)

k3 (sec-1)

Liver

0.0195
+/- 0.022

0.133 +/0.113

0.0055 +/0.0024

0.0134 +/0.0094

0.074 +/0.066

0.0092 +/0.012

Lung

6.8x10-4
+/- 3.7
x10-4

0.29 +/0.21

0.0019 +/0.0011

0.0161+/0.0094

0.48 +/0.39

0.0031 +/0.0036

Table 4. 3: Rate Constants of ICG Pharmacokinetics in the Lung and Liver of Healthy
Mice and Mice with Liver Disease. The observed increase in ICG rate constants of lung
is associated with the experimentally induced endothelial cell apoptosis and vascular
lesions after FasL administration. The slow excretion rate of ICG from the systemic
circulation in mice with liver disease compared to healthy mice can be associated to the
sluggish ICG uptake rate of the liver in mice with liver disease. ICG is mainly cleared
through the liver into the bile without undergoing any modification.
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4.4

Discussion
Dynamic FMT systems can be used to determine the biodistribution of a multitude

of injectable agents and can be used in conjunction with organ specific dyes to acquire a
general assessment of organ function. We presented DyFMT as preclinical imaging tool
for assessing alterations in fluorescent tracer pharmacokinetics pharmacokinetics and
biodistribution in relation to disease states.
In this study, we imaged healthy and diseased mice with high temporal resolution,
during the disappearance of ICG from systemic circulation, the heart, and its time
resolved uptake in the liver and lung. ICG is a well-characterized probe, approved for a
variety of clinical endpoints such as measuring the hepatic blood flow to test liver
function (El-Desoky et al.; Kimura et al.; Ott; Seifalian et al.). ICG binds to plasma
proteins, such as albumin, and is mainly removed from the circulation by the liver (Ott;
Berezin, Guo, Akers, et al.). Dynamic fluorescence mediated tomography (DyFMT) was
made possible by co-registering data collected using our fiber based, video-rate FMT
system (Metasebya Solomon et al.) with preclinical microCT data as an anatomical
reference. To extract ICG concentration over time from our DyFMT data in selected
regions of interest, we choose three ROIs, one in the heart, lung and in liver based on
manual segmentation guided by anatomical x-ray CT projections.
A measurement of the input function is required for most models characterizing the
kinetic behavior of substances of interest in tissue in vivo. Measurement of the plasma
input function enables accurate quantification of dynamic FMT data. Derivation of the
input function from DyFMT images is the most attractive method because of its noninvasive nature and because it simplifies the scanning protocol. Therefore, we
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demonstrated the feasibility of implementing time traces from the heart region as imagederived forcing function. We demonstrated that there is high temporal correlation
between IDIF and its corresponding reference arterial blood samples for each mouse.
Obviously, blood sampling is very invasive and very inconvenient for small animal
imaging especially due to their small blood vessels and small blood volume. The mean
Pearson r-values were 0.95 ± 0.024 and 0.86 ± 0.083 in healthy mice and in mice with
liver disease respectively.
We demonstrated the feasibility of distinguishing the uptake rate of two different
organs, lung and liver. The overall ICG uptake rate of liver was hundredfold higher than
the lung as expected since ICG is mainly cleared through the liver. Furthermore, we
demonstrated the feasibility of distinguishing healthy vs. diseased organs based on
significant difference between the estimated ICG kinetic rate constants of liver and lung
regions in healthy mice and mice with hepatic disease. For instance, we observed a
decrease in plasma clearance of ICG in diseased mice, which is associated with the slow
transport rate through the plasma membrane of hepatocyte. The estimated k1 value,
which decreased from 0.02 ± 0.022 in healthy mice to 0.013 ± 0.0094 in diseased mice,
successfully predicted the status of the hepatic function. In addition, we observed an
increase in the ICG rate constants of the lung and liver. The average overall ICG uptake
rate of liver and lung, for instance, increased from 7.4x10-4 to 1.48x10-3 sec-1 and 4.46x10-6
to 1.03x10-3 sec-1, respectively. The fitted ICG concentration curves generated using the
two-compartment model showed high temporal correlation with the corresponding lung
and liver ICG time courses data in healthy mice and mice with liver disease (r-values
were 0.95 ± 0.059 and 0.95 ± 0.028 for lung and liver regions of healthy mice
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respectively and 0.92 ± 0.047 and 0.92 ± 0.042 for lung and liver respectively in diseased
mice). The difference between healthy and diseased mice kinetic parameters of the lung
and liver is associated with the induced morphological changes of cell bodies and the
nucleus (in liver) and endothelial cells that express Fas receptors (in both lung and liver)
as previously shown in the literature (Goetz et al.; Janin et al.; Ogasawara et al.).
Previous two-dimensional fluorescence reflectance imaging (FRI) has been used to
monitor the biodistribution of newly developed contrast agents and effects of drugs on
excretory systems function (Achilefu and Dorshow; Hillman and Moore; Hillman et al.;
Welsher, Sherlock and Dai; Amoozegar et al.). For instance, dynamic imaging via
fluorescence reflectance imaging (FRI) recently allowed segmentation of various internal
organs (Hillman and Moore; Welsher, Sherlock and Dai); In addition, Amoozegar et al.
has further demonstrated the capacity of dynamic FRI to evaluate healthy and diseased
organs based on the presence of abnormally altered time courses (Amoozegar et al.). The
study showed change in ICG uptake rates in the liver and kidney following liver damage
compared to healthy animals by visual assessment and comparison with ex-vivo studies.
The strength of the current DyFMT-CT study is that we further extended this approach
by implementing a two-compartment model to quantify the extent of damage on the
target organs based on the changes of the kinetic parameters. Furthermore, the current
DyFMT-CT system has improved deep tissue sensitivity, volumetric localization and
increased quantitative accuracy compared to the dynamic FRI.
The feasibility of fluorescence tomography for in vivo dynamic imaging has been
previously reported (Alacam and Yazici; Alacam, Yazici, Intes, et al.; Alacam, Yazici,
Intes, Nioka, et al.; Alacam, Yazici, Serdaroglu, et al.; Cuccia et al.). For instance, Liu et
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al. quantified the uptake and washout rate of ICG in the liver, where optical imaging was
acquired at a 1.1 min/frame using their hybrid fluorescence DOT and micro-CT system
(Liu et al.). The rate constants (uptake rate (k1=0.0036 sec-1) and washout rate of
(k3=0.00069 sec-1)) were ten times slower than we predicted, which could be associated
to the slow acquisition rate incapability to capture the fast dynamics of liver. Moreover,
their image acquisition time, 1.1min/frame is unsuitable for capturing fast dynamics of
the first few minutes in regions such as the heart, although it may be adequate for the
slow dynamics of the liver. In addition, image acquisition times in the range of minutes is
unsuitable for capturing the early fast-changing signals associated with various optical
contrast agents. To a significant extent, the system presented in this paper addresses
many of these difficulties.
The difficulty in FMT image segmentation is compound by the low spatial
resolution in optical imaging, which rapidly degrades with imaging depth due to the high
scattering of light in tissues (Hillman et al.). Therefore, optical imaging can leverage
anatomical

information

to

improve

accuracy

during

processing

and

image

reconstruction. For instance, we implemented manual segmentation to extract relative
ICG concentration from three target regions. An important future area of work is in
incorporating automatic or semi-automatic statistical clustering algorithms. The
possibility of implementing segmentation algorithm to delineate the different organs
based on differences in the kinetics of injected contrast agents also remains a question
for future investigation. Another limitation of low spatial resolution is spillover and
partial volume effects that would affect the accuracy of ROI based input functions. The
spillover and partial volume effects on the selected ROIs have not been corrected for in
113

this study. Therefore, another area of future work is to adapt spillover and partial volume
correction algorithms developed for dynamic PET and MRI imaging systems for
DyFMT platform (Fang and Muzic; Laforest et al.; van der Weerdt et al.; Wu, Hoh, et al.;
Wu, Huang, et al.). With these improvements, the accuracy of IDIF would remain
consistent across multiple optical contrast agents despite the variance introduced by their
different perfusion rates.
The current FMT system setup has high dynamic range and linear response and
accurate localization at various depths as shown in previous studies (Metasebya Solomon
et al.). However, several potential improvements of the fiber-based, video-rate FMT
system can still be identified. Possible extensions on the current design include extending
the FMT field of view for whole-body imaging. The DOT imaging array shape and size
can be designed based on the individual application. For example, the imaging array
could have a cylindrical shape with extended sources and detectors for whole-body
coverage. The potential for an expanded fiber array system with up to 48 sources and 48
detectors has been demonstrated for brain imaging in humans (White et al.). A higherdensity imaging array could also potentially increase the resolution, particularly at the
shallower depths for accurate estimation of the IDIF (Culver, Ntziachristos, et al.).

4.5

Conclusion
In this study, we presented video-rate, fiber-based FMT, a non-invasive in vivo

imaging tool for quantitative pharmacokinetics and biodistribution studies. We imaged,
with high temporal resolution, the disappearance rate of ICG from systemic circulation
and its time-resolved uptake and clearance in the liver and lung in healthy mice and mice

114

with experimentally induced acute hepatic apoptosis. In addition, we validated the
feasibility of implementing time traces extracted from highly vascularized region-ofinterest as a forcing function rather than acquiring arterial blood samples invasively. The
time courses of the heart region are used as an image-derived input function for a twocompartment model to compute the uptake and clearance rate of ICG from the lung and
liver regions. Comparisons between the ICG kinetics parameters before and after drug
treatment demonstrate the capacity to assess organ function and drug-related acute
toxicity. Although we have used a linear compartment model in these studies, more
complex models could be used successfully. In summary, tracer kinetic modeling
combined with fluorescence dynamic tomography provides a powerful pharmacokinetic
analysis tool using newly developed diagnostic optical agents with a potential for
detecting the disease state affecting internal organs and monitoring their response to
therapeutic agents.
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Chapter 5
Detection of Enzyme Activity in
Orthotopic Murine Breast Cancer by
Fluorescence Lifetime Imaging Using
Fluorescence Resonance Energy
Transfer-based Molecular Probe
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5.1

Introduction
Molecular signatures of cancer tissues include up-regulated signaling receptors and

enzyme expression. For example, up-regulation of integrin receptors in tumors is
associated with metastatic spread (Sloan et al.). Likewise, increased activity of members
of the matrix metalloproteinase (MMPs) family by in cancer tissue can also be an
indication of metastatic potential (Roy, Yang and Moses). Enzyme activity can be
diagnostic and prognostic in cancer and other diseases. For instance, MMPs are
biomarkers for diagnosis and prognosis in cancer as they have been implicated as
mediators of tumor growth, invasion and metastasis (Bremer, Tung and Weissleder;
Himelstein et al.; Fingleton; Weissleder et al.). MMP inhibitors are under investigation as
anti-cancer agents (Roy, Yang and Moses).
Preclinical optical imaging with fluorescent contrast agents has become prominent in
recent years due to the high sensitivity and high throughput nature of this versatile
modality. Fluorescent molecular probes can be administered for rapid detection of
disease throughout the body of small animals, economically and without ionizing
radiation. Fluorescence techniques can be further enhanced by sensing mechanisms such
as spectral shifts, quenching and fluorescence lifetime changes that may occur due to
molecular interactions and environmental conditions. Optical imaging with fluorescent
molecular probes is an economical, high throughput modality for non-invasive detection
these cancer signatures in animal models of cancer.
Fluorescent molecular probes include “always on” agents that rely on target binding
in tissues or “activatable” agents that report molecular interactions by signal
enhancement mechanisms. For “always on” agents, measured fluorescence intensity is
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used as a measure of concentration in tissue, similar to nuclear imaging. An example
would be a ligand for an up-regulated receptor that bears a near-infrared (NIR) dye such
as IS750. This contrast agent has a high affinity for the αvβ3 integrin receptor (ABIR)
and has been used in experimental animal models for imaging tumors. Activatable
probes used in fluorescence-based imaging are optically invisible or at least display
reduced fluorescence until molecular activation at the disease site. These include enzyme
substrates with fluorescent dyes in close proximity which often employ fluorescence
resonance energy transfer (FRET) in addition to other quenching mechanisms (Berezin
and Achilefu). The enhancement of fluorescence intensity at the site of disease may be
great enough in intensity for visualization, but may not totally reflect molecular events
within the disease site. Measurement of fluorescence lifetime alteration can be
additionally utilized to verify that the observed fluorescence is indeed mediated by a
molecular target and not from other processes(Chang et al.).
Fluorescence lifetime is an intrinsic property of fluorescent reporters that is not
dependent on concentration but can reflect changes in the environment. Often, the
quantum yield is directly related to the fluorescence lifetime: quenching of the
fluorescent reporters in an enzyme activatable probe results in lower quantum yield and
shortening of the molecular probe’s fluorescence lifetime. In the intact FRET pair, the
quantum yield and the lifetime of the donor are lower due to the transfer of the
excitation energy of the donor to the acceptor (Berezin and Achilefu). Both the quantum
yield and the lifetime are subsequently restored to the free dye values after proteolysis
leading to an increase in fluorescence intensity and lifetime values of the donor.
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Figure 5.1 shows a schematic of the mechanism of action of enzyme activatable
probe such as the one used in this study. The donor (D) is a NIR fluorescent reporter
attached via a cleavable peptide linker to an acceptor (A) molecule. The absorption
properties of the acceptor overlap with the emission properties of the donor attenuating
fluorescence and shortening lifetime of the donor. Upon enzyme-mediated hydrolysis,
the emission properties of the donor are restored. Previously reported protease
activatable molecular FRET probes have shown to improve the tumor detection
sensitivity using the intensity signal (Mahmood and Weissleder; Scherer, McIntyre and
Matrisian). In this report, we demonstrate that fluorescence lifetime measurement
confirms that the observed fluorescence in the syngeneic tumor is, in part, a result of
MMP-mediated hydrolysis and subsequent liberation of the proteolytic fragments from
close proximity that caused the initial quenching.
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Figure 5.1: Cartoon of FRET-based fluorescent molecular probe and restoration of
fluorescence after enzyme mediated hydrolysis of the connecting peptide by protease
enzymes. The fluorescence quantum yield and fluorescence lifetime of the donor are
increased as the donor and acceptor are separated. In the case of MMP750, the donor
and acceptor are identical fluorophores.
Herein, we examined an MMP-sensitive activatable fluorescent construct and an
“always-on” ABIR-targeted fluorescent probe in a murine orthotopic breast cancer
model using both fluorescence intensity and fluorescence lifetime imaging. While both
agents produced good tumor contrast in this model, only the activatable probe showed a
significant increase in fluorescence lifetime validating the upregulated enzyme activity
due to presence of the tumor. This study demonstrates the potential of fluorescence
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lifetime imaging for improving the knowledge of whether the molecular events that are
observed are actually target related with FRET-based activatable probes.

5.2

Methods

5.2.1

in vitro Spectroscopy In vitro Spectroscopy

IntegriSense 750 (IS750) and MMPSense 750 FAST (MMP750) were purchased
from VisEn Medical (Bedford, MA) and prepared according to manufacturer’s
instructions. IntegriSense750, MMP750 and MMP-activated MMP750 were diluted in
4% (w/v%) bovine serum albumin (BSA) in phosphate buffered saline (PBS) for
spectroscopy. A 20 µL MMP750 solution was then added and incubated at 37 ºC for 3
hr. Activation of MMP750 was confirmed by an increase in fluorescence intensity in
cuvettes (ex/em: 740/755-900 nm) of the activated solution relative to the control
solution under identical conditions. Fluorescence lifetime (FLT) measurements were
performed with using 780 nm NanoLed® (impulse repetition rate 1 MHz) excitation at
90º to the a time-correlated single-photon-counting detector at 820 nm, 26 nm bandpass
(Horiba). The fluorescence lifetime was recorded on a 50 ns scale until a peak of 5,000
counts. The instrument response function was obtained using a Rayleigh scatter of
Ludox-40 (0.05% in water) in an acrylic transparent cuvette at 780 nm emission. Decay
analysis software (DAS6 v6.1; Horiba) was used for lifetime calculations. The goodness
of fit was judged by χ2 values, Durbin–Watson parameters, as well as visual observations
of fitted line, residuals, and autocorrelation functions.

121

5.2.2

In vivo Imaging

All animal studies were performed according to protocols approved by at
Washington University School of Medicine Animal Studies Committee for humane care
and use of laboratory animals. Luciferase-transfected 4T1 mouse mammary carcinoma
cells (4T1luc, Sibtech, Brookfield, CT) cultured in DMEM media were injected
subcutaneously into left and right mammary fat pads.
Mice were anesthetized with ketamine (85 mg/kg) and xylazine (15 mg/kg), IP for
depilation, intravenous injections and initial post-injection imaging. For extended and
subsequent imaging, isoflurane gas (2% v/v in 100% O2) was delivered via nosecone for
maintenance of anesthesia. Imaging agents were administered according to
manufacturer’s recommendations, 1 nmol per mouse, via lateral tail vein of 6-8 week-old
female balb/c nude mice (n=3) provided by NCI (NIH).
Time-domain diffuse optical imaging of living mice was performed using the
eXplore Optix MX2 system (Advanced Research Technologies, Montreal, Canada) as
reported previously (S. Achilefu, S. Bloch, et al.). Briefly, the animals were positioned
supine on the heated imaging platform. Pre-injection scans were performed to assess
background and autofluorescence signals. Scans were again performed immediately postinjection and at 4-6 hr and 24 hr post-injection. Regions of interest including tumor and
non-tumor tissue were raster-scanned at 780 nm excitation with emission detection
centered at 830 nm in 1.5 mm steps. Fluorescence intensity and lifetime values were
determined by integration or single exponential fitting of the acquired temporal point
spread function (TPSF) fluorescence decay curves for each measurement using Optiview
software (Advanced Research Technologies). Images were created by mapping each
122

value to the corresponding location on a white light reference image of the mouse. Mean
fluorescence intensity and lifetime values for tumor and non-tumor tissue regions of
interest (ROI) for each mouse were selected and reported for analysis.
For reference and ex vivo fluorescence biodistribution assays, images were also
captured using the Pearl NIR fluorescence imaging system (LiCor Biosciences, Lincoln,
NE). The biodistribution of probes was assessed using the simple method described
previously (S. Achilefu, R. B. Dorshow, et al.; Bugaj et al.). At 24 h post-injection,
aliquots of blood and pieces of major organs (tumor, heart, kidney, lung, spleen,
stomach, intestine, muscle, liver, skin and brain) were harvested and placed on a clear
plastic petri dish for imaging. Fluorescence images were acquired as described above.
Mean fluorescence intensity was determined for each tissue by ROI analysis and
combined for each group for statistical analysis.

5.2.3

Statistical Analysis

Mean fluorescence intensity and FLT values of ROIs for each group were compared
using student’s t-test with α = 0.05 set for significance. Fluorescence biodistribution
ROI data were averaged for each organ tissue for IS750 and MMP750 and plotted
together for comparison.

5.3

Results
The in vitro activation of MMP750 by the enzyme led to the significant (~2X)

increase in fluorescence as shown in Figure 5.2A. Such increase in fluorescence was
apparently due to the enzymatic cleavage of the peptide linker leading to the separation
of the donor from the acceptor. As expected, a simultaneous increase of the decay slope
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(Figure 5.2B) demonstrated an increase in the fluorescence lifetime from 0.58 ns to 0.73
ns, unequivocally demonstrating a reduction in FRET.

Figure 5.2: (A) Fluorescence steady state spectra of MMP750 before and after
enzymatic activation by MMP-2 for 3 hr. The increase in fluorescence intensity
confirmed partial activation by enzyme-mediated hydrolysis. (B) Fluorescence decays of
MMP750 before and after MMP treatment demonstrating a shift in FLT from 0.58 ns to
0.73 ns due to decreased FRET efficiency after activation.
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Having demonstrated the fluorescence lifetime increase in MMP750 upon
interaction with MMP and stable fluorescence lifetime of IS750, we administered the
probes into small animal tumor models for in vivo imaging. Both IS750 and MMP750
showed tumor-specific uptake in vivo by fluorescence intensity imaging (Figure 5.3A).

Figure 5.3: (A) Planar fluorescence imaging of mouse with orthotopic breast tumors at
6 and 24 hr after injection of MMP750. (B) Fluorescence biodistribution image (inset)
and ROI data for organ tissues 24 hr after injection of either MMP750 or IS750. Arrows
indicate 4T1luc tumors.
Fluorescence intensity values were highest for the ABIR-targeted probe immediately
after injection in the tumor and non-tumor regions and decreased with time. In contrast,
MMP750 was relatively silent after injection and fluorescence signal increased with time,
particularly in the tumor regions. Ex vivo tumor fluorescence at 24 h post-injection was
higher in the tumor than other tissues (Figure. 5.3B), with 20-fold higher than muscle for
both probes (n=3). Autofluorescence and signal from the GI tract was less than 10% of
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the signal after molecular probe administration and did not affect the measurement of
fluorescence intensities or lifetimes.
Example fluorescence decay curves and nonlinear regression fits are given in Figure.
5.4. Laser power and integration time were automatically adjusted during scanning to
ensure adequate photon counts for fitting. The tails of the TPSF curves were fit from 26 ns (Figure. 5.4, black lines) for image map construction.

Figure 5.4: Representative normalized fluorescence decay curves (TPSF) in vivo FLT
imaging tumor ROIs with single exponential least squares nonlinear regression (black
line) from 2 ns to 6 ns (shaded) for MMP750 post-injection (MMP750t0) and 4 h postinjection (MMP750t0) and for IS750 post-injection (IS750t0).
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Figure 5.5: Fluorescence intensity and lifetime maps of mice with orthotopic 4T1luc
breast tumors immediately after (A and C) and 4-6 hr after (B and D) injection of
MMP750. The fluorescence intensity maps show low fluorescence immediately after
injection (A) and high signal from the tumors at 4-6 hr after injection (B, arrows). The
fluorescence lifetime map is relatively flat with average FLT of 0.63 ns immediately after
injection (C). At 4-6 hr after injection, the tumor areas show a higher FLT (0.76 ns)
relative to non-tumor regions. Corresponding image maps show different behavior for
the “always on” probe. The fluorescence intensity maps show higher signal immediately
after injection (E) and from the tumors at 4-6 hr after injection (F, arrows). The
fluorescence lifetime map is relatively flat immediately after injection (G). At 4-6 hr after
injection, the tumor areas show a shorter FLT relative to non-tumor regions (H).
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Intensity maps created by integration of the fluorescence decay curves produced
image maps showing good tumor contrast. The fluorescence intensity of MMP750 was
very low immediately after injection and increased about 10-fold by 6 hr post-injection
(Figure 5.5A and 5.5B, respectively). On the other hand, IS750 fluorescence was high
immediately after injection (Figure 5.5E). Fluorescence signal from the tumor regions
was significantly higher (P<0.01) for animals in both groups by 6 hour post-injection
(Figure 5.5B and 5.5F).
In vivo FLT imaging showed that the measured tumors FLTs for MMP750 were
elevated at 4-6 hour post-injection (Figure 5.5D) relative to earlier time points (Figure
5.5C). The FLT maps showed a more diffuse pattern than the intensity maps with
increase in FLT in the tumor and peritumoral regions. For IS750, the FLT maps were
relatively flat at corresponding time points (Figures 5.5G and 5.5H). FLT values from in
vivo ROI analysis are shown in Figure 5.6.
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Figure 5.6: Graphical comparison of in vivo FLT values for tumor ROIs immediately
after (post-inj) and at 4-6 hour after intravenous administration of NIR fluorescent
molecular probes. The measured FLT values for MMPSense750 FAST at 4-6 hr were
significantly higher (*P<0.01) than post-injection. FLT values were not significantly
different for these time points with IntegriSense750.
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For MMP750, the fluorescence lifetime was 0.63+/-0.02 ns immediately postinjection and increased with time. At 4-6 hr post-injection, the FLT had increased
significantly (P<0.01) to (0.76+/-0.02 ns) in the tumor region. For IS750, the average
FLT values did not change significantly (1.11+/-0.01 ns immediately post-injection and
1.10+/-0.03 ns at 4-6 h post-injection). In the tumor regions, FLT values were slightly
lower (1.09+/- 0.03 ns) than non-tumor regions (1.11+/-0.03 ns). Expression of MMP-2
and MMP-9 in the 4T1luc tumor tissues was confirmed by immunohistochemistry
(Figure 5.7).

Figure 5.7: H&E stained section of orthotopic 4T1luc tumor tissue (A) and
immunohistochemistry for MMP-2 (B) and MMP-9 (C). Brown color indicates areas
with high MMP expression in these tumors.

130

5.4

Discussion
Enzyme activatable fluorescent probes promise higher disease-specific contrast

relative to “always on” targeted molecular probes by fluorescence enhancement only
within the tissue of interest. The contrast enhancement mechanism of fluorescence
activation is unique to optical imaging. Detection of cancer-related enzyme activity using
protease-activatable fluorescent probes has high potential for use in staging of primary
cancers and detection of metastases.
In the current study, excellent tumor-specific contrast was achieved within 4-6 hr
after injection with both the activatable MMP-sensitive and “always on” integrin-targeted
NIR fluorescent molecular probes in the orthotopic breast cancer model. The orthotopic
breast tumors developed from implanted 4T1 cells syngeneic to the balb/c mouse line
are known to produce metastases to the lung and lymph nodes (Tao et al.). This
aggressive tumor model is representative of fast-growing and invasive human breast
cancer. MMP activity and ABIR expression are biomarkers of breast cancer considered
to indicate the aggressiveness of the disease (Daniele et al.; McGowan and Duffy)..
The molecular targets, MMPs and ABIR, are ubiquitously expressed in both target
and non-target tissues, although at unequal levels (Roy, Yang and Moses; Sloan et al.).
Thus it is not surprising that some fluorescence signal is observed in non-target tissues.
Enhancement of signal from the MMP probe was observed in these tissues and results in
some fluorescent background rendering the tumor-to-normal contrast produced by this
agent almost equal to that of the “always on” fluorescent probe. It is therefore
imperative that the activation of this probe be established to distinguish enzyme activity
from other modes of contrast including nonspecific accumulation. The activation of
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MMP750 was confirmed in this study by the change in FLT that resulted from reduction
in FRET as the peptide sequence was cleaved as depicted in Figure. 5.1. FLT imaging
provides confirmatory evidence of activation by detecting changes in FRET.
Unsurprisingly, the FLT increase due to activation of MMP750 is seen in the tumor
tissue and the surrounding mammary tissue as well (Figure. 5.5D). High MMP activity in
the tumor periphery is expected as MMPs are expressed within the tumor stroma and on
the invasive front (Roy, Yang and Moses). Thus the FLT map demonstrates the real
MMP activity in tissue rather than just accumulation. This study shows that detection of
molecular probe activation using FLT-based imaging has significant advantages over
other strategies such as inclusion of a spectrally distinct, reference fluorescent reporter
either co-injected (Baeten et al.) or as part of the probe construct (Scherer, McIntyre and
Matrisian). The use of a single fluorophore as both donor and acceptor facilitates
synthesis of activatable probes, providing that adequate quenching is established.
A shortcoming of enzyme-activatable probes, that is not often discussed, is whether
there is significant tumoral accumulation of fluorescent proteolytic fragments that were
activated distal to the tumor site. Accumulation of the proteolytic fragments might
exaggerate the apparent enzyme activity within the tumor tissue. Further studies are
needed to assess this type of nonspecific activation and the fates of the probe fragments
within the body. Fluorescent probes with improved enzyme selectivity will improve
detection and differentiation of cancer-related enzyme activity from other causes such as
inflammation (Bremer, Tung and Weissleder). MMP750 resulted in exceptional tumorspecific contrast by fluorescence intensity that was apparently enzyme mediated. Good
tumor-normal contrast was obtained within 4-6 hr after injection, a significant
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improvement over larger, polymeric activatable probes which require 8-24 hr (Baeten et
al.).

5.5

Conclusion
For quantitative measurement of enzyme activity, nonspecific activation must be

minimized or other methods developed to separate the level of activation from that of
concentration. Here we have presented FLT imaging as one possibility. FLT imaging has
the potential for directly assessing changes in FRET due to enzyme activity and is
relatively simple and inexpensive relative to other methods such as reference probe coadministration and multimodal imaging. Measurement of the change in FRET upon
activation was performed using a single excitation/emission and simple data analysis.
FLT imaging using NIR fluorescent FRET probes is a promising technique that has
translational potential in regions accessible to optical imaging such as skin, GI and breast
cancers. This technique may also be useful for fluorescence guidance of surgery.
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